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Preface 
This edition deals mostly with the peripheral 
benzodiazepine binding sites on blood cells and with 
changes of their affinity under tranquillizers and 
GABAergic compounds. The other topic concerns 
several new data on the role of voltage-sensitive 
calcium channels in the development of benzo­
diazepine abstinence, and also interactions between 
calcium channel blockers and of agonists of dopamine, 
serotonin and m-cholinoreсерtors (Zharkovsky et 
al. ). Some papers deal with vasoactive peptide 
receptors and with the pharmacology of 
cholecystokinin-8 agonists. There have been included 
also couple of reviews and methodological papers. 
This year professor of our department Leo Nurmand 
celebrated his 60. birthday. He has been active more 
than 35 years in planning and developing the teaching 
process in pharmacology and not only in pharmacology, 
but also in several other topics in our Medical 
Faculty. This volume includes his paper on the 
development in teaching of pharmacology in Tartu 
University after WWII. 
The volume is devoted to him, teacher, gentleman 
and humanitarian. 
Lembit H. Allikmets 
Chairman, Dept. of Pharmacology 
Dean, Faculty of Medicine 
THE EFFECT OF STRESS ON 0U3 BENZODIAZEPINE 
RECEPTORS IN RAT BLOOD PLATELETS AND 
LYMPHOCYTES: THE EFFECT OF 
NONBENZODIAZEPINE TRANQUILIZERS 
L. Rago, A. Adojaan and P. Pokk 
Department of Pharmacology, Tartu University 
Abstract 
The effect of several models of stress was studied 
on 0U3 (peripheral-type) benzodiazepine receptors in 
rat blood platelets and lymphocytes. Electric 
footshock lowered significantly ^ H-Diazepam binding 
on blood platelets whereas swimming stress and 
chronical injection enhanced the number of ^H-Ro 
5-4864 binding sites both on platelets and lym­
phocytes. Nonbenzodiazepine tranquilizers phenibut 
and buspirone after in vivo administration had 
different effects on blood cell benzodiazepine 
receptor. Phenibut (100 mg/kg) significantly en­
hanced the affinity and had a tendency to lower 
number of ^h-Ro 5-4864 binding sites on platelets. 
Buspirone (5 mg/kg) was without any effect. The 
pretreatment of animals with phenibut (100 mg/kg) 
counteracted the effect of swimming stress on coj 
benzodiazepine receptors both on platelets and 
lymphocytes. Buspirone (5 mg/kg) did not have any 
effect on the swimming stress induced changes of 
^H-Ro 5-4864 binding on platelets but had a tendency 
to lower the enhanced binding on lymphocytes. The 
possible mechanisms involved in the changes of 0J3 
benzodiazepine receptors on blood cells after 
various stressful stimuli is discussed. The 
possibility to use blood cell benzodiazepine re­
ceptors as sensitive markers of emotional status 
(anxiety) in humans is suggested. 
Introduction 
Specific benzodiazepine (BD) binding sites in 
the brain and in several other tissue outside the 
central nervous system were discovered a decade ago 
using tritiated diazepam as a ligand [20]. The 
central BD binding sites, mostly referred now as BD 
receptors, are coupled to the GABA receptor -
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Chloride ionophore complex. The BD receptor ligands 
modulate the efficacy of GABA as an inhibitory 
transmitter. Depending on the chemical structure of 
the ligand the modulation is either positive (GABA 
action enhanced) or negative (GABA action depressed) 
[2]. Multiplicity of central BZ receptors has been 
proposed. The binding of ß-carboline derivatives 
has been used to demonstrate at least two different 
binding sites (BDi and BD2) in the rat brain 
[2].Moreover, the so called peripheral BD receptor 
is also present in the central nervous system [1, 
19]. Therefore, recently a new nomenclature of BD 
receptors that does not designate location and is 
defined in terms of pharmacological specificity has 
been proposed. The Greek letter omega, as ca^, ca^ 
and CAJ3 to designate respectively the central BD^, 
BD2 and the peripheral BD receptors has been used 
[И]. 
Several lines of evidence demonstrate that 
central BD receptors are affected by stress [14, 
15]. However, little is known about the influence 
of stress on the peripheral type BZ recognition 
sites [19]. The aim of the present study was to 
examine the action of various kind of stressful 
stimuli on Ш3 BD receptors in rat blood platelets 
and lymphocytes. In addition to this the effect of 
nonbenzodiazepine tranquilizers on stress induced 
changes of ca> j BD receptors on the blood cells was 
studied. 
Materials and methods 
Animals and drugs. Male albino laboratory rats 
weighing 230-280 g (Rappolovo Farm, Leningrad) were 
used. The animals were maintained on food and water 
ad libitum at 20 ± 1 С on a reversed lighting cycle 
with lights off from 2000 to 0800. Phenibut hy­
drochloride [ß-(phenyl)-GABA] and buspirone hy­
drochloride (Bristol-Myers, Evansville, IN, U.S.A.) 
were dissolved in saline. Both drugs were injected 
in a volume of 1 ml per kg intraperitoneally 50 and 
40 min prior to experiments respectively. 
Forced swimming stress. Swimming stress was 
carried out as described previously [14] with minor 
modifications. The stress was produced by forcing 
the rats to swimm in a water basin (50 x 40 x 25 
cm) at 20 ± 1 °C for 5 min. After termination of 
the forced swimming the animals were immediately 
sacrificed by decapitation. 
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Foot shock stress. The foot shock stress involved 
a series of electrical foot shocks delivered in 
individual boxes with floors made of brass rods, 1 
cm apart. Shocks were provided by a stimulator which 
delivered shocks (60HZ, 0.5mA) during 10 s with 5 
s intervals during a 5 min session. 
Chronical injection stress. It was proposed that 
chronical injection procedure itselt may be 
stressful. In chronical treatments with various 
drugs usually only two groups are compared: chronical 
vehicle and chronical drug. In this case 
stress-protective drug may demonstrate results that 
are not due to any specific action. Before carrying 
out chronical experiments with specific <a>j  BD re­
ceptor ligands we decided to clarify this problem. 
Therefore we decided to compare chronically injected 
animals (1 ml/kg of saline once a day during 10 
days) to the group of animals receiving only one 
inj ection. 
In vitro binding studies. After decapitation the 
trunk blood of every rat was collected into a plastic 
tube containing 0.5 ml acid citrate dextrose (ACD) 
anticoagulant. Lymphocytes were isolated according 
to the method of Boyum [3] using Ficoll-Pague 
gradient and were washed twice before the binding 
experiment. Platelets were obtained from 
platelet-rich plasma by centrifugation. The pooled 
blood cells from at least 8 animals were for each 
binding assay. ^H-Diazepam (spec. act. 81 Ci/mmol) 
and 3h-Ro 5-4864 (spec. act. 84 Ci/mmol, both Am-
ersham Radiochemicals, England) were used in eight 
different concentrations (0.5 - 34 nM and 0.5 - 24 
nM respectively) for labelling peripheral-type BZ 
binding sites on blood platelets or lymphocytes. 
Unlabelled Ro-4864 (Hoffman - La Roche, Basel, 
Switzerland) was used to determine nonspecific 
binding. The binding experiments were performed in 
a total volume of 125 ц.1 during 30 min at 0 °C. All 
binding experiments were carried out in a modified 
Hanks solution (pH 7.3). The intact blood platelets 
and lymphocytes were used throughout these studies. 
After incubation of the tubes containing lym­
phocyte or platelet suspension the reaction was 
stopped by rapid filtration over Whatman GF/B 
filters. The filters were washed with 3 x 3 ml of 
ice cold buffer. Specific binding was calculated by 
subtracting the nonspecific from total binding at 
each given radioactivity concentration. Protein was 
measured by the Lowry et al [12] method. 
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Calculations and statistics. Maximum binding 
(B m a x) and affinity constants (Kp) were calculated 
using the Scathard plot analysis. The Scathard plots 
were computed using linear regression programm. For 
the data presented, only the plots with a correlation 
coefficent of 0.85 or more were accepted. 
The significance of the differences between the 
results was tested using Student's t-test; P < 0.05 
was considered significant. 
Results 
The effect of foot shock on BD receptors in 
rat blood platelets and lymphocytes. The 
short-lasting (5 min) electric foot shock lowered 
the number and decreased the affinity of ^ н-Diazepam 
binding sites on blood platelets. On lymphocytes 
the effect of foot shock was less evident (table 
1 ) .  
Table 1 
The effect of foot-shock stress on benzodiaze­
pine receptors in rat blood platelets and lympho­
cytes. Зн-Diazepam was used to label benzodiaze­
pine binding sites on intact blood cells. The 
data expressed are mean ± S.E.M. of at least 
three indipendent experiments each carried out in 
triplicate. 
Experimental 
group 
зН-Diazepam binding 
Bmax (fmol/108 
cells) 
KD (nM) 
Platelets 
Control 488 ± 53 9.6 ± 1.6 
Foot-shock 321 ± 41* 12.2 ± 2.1 
Lymphocytes 
Bmax (fmol/106 
cells) 
KD (nM) 
Control 108 ± 21 8.7 ± 1.3 
Foot-shock 88 ± 11 9.8 ± 1.2 
* P < 0.05 as compared to control animals 
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The effect of forced swimming stress on 0J3 BD 
receptors in rat blood platelets and lymphocytes. 
Forced swimming stress increased the number of ^ H-Ro 
5-4864 binding sites both on platelets and on 
lymphocytes. Those changes were statistically 
significant. The affinity for the ligand was slightly 
decreased but the changes were never statistically 
significant (table 2). 
Table 2 
The effect of swimming stress on ^ h-Ro 5-4864 
binding in rat intact blood platelets and lympho­
cytes . The data expressed are mean ± S.E.M. of 
five experiments each carried out in triplicate. 
Experimental 
group 
Зн-Ro 5-4864 binding 
Bmax (fmol/mg) KD (nM) 
Platelets 
Control 5895 ± 450 0
 
H- 0
 
00
 
Swimming stress 8931 ± 930* 12.3 ± 1.4 
Lymphocytes 
Control 4737 ± 580 8.2 ± 1.1 
Swimming stress 8016 ± 1108* 0
 
00
 
H-
* P < 0.05 as compared to control group 
The effect of chronical injection of saline on 
0J3 BD receptors in rat cerebral cortex, blood 
platelets and lymphocytes. The chronical injection 
procedure caused marked changes in oug BD receptors 
(table 3). The number of ^H-Ro 5-4864 binging sites 
was increased not only on platelets and lymphocytes 
but also in cerebral cortex. However, the changes 
in cerebral cortex did not reach statistically 
significant values. The affinity for the ligand was 
not considerably changed in this series of ex­
periments (table 3). 
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Table 3 
The effect of acute and subchronical injection of 
saline on ujj benzodiazepine receptors in rat cer­
ebral cortex, blood platelets and lymphocytes. 
^H-Ro 5-4864 was used to label benzodiazepine re­
ceptors. The data expressed are mean ± S.E.M. of 
at least three indipendent experiments each car­
ried out in triplicate. 
Experimental 
group 
Зн-Ro 5-4864 binding 
Bmax (fmol/mg) KD (nM) 
I. Cerebral cortex 
Acute injection 111 ± 12 2.03 ± 0.21 
Chronical injec­
tion 
147 ± 15 2. 15 ± 0.33 
II. Platelets 
Acute injection 4860 ± 630 9.9 ± 1.1 
Chronical injec­
tion 
7530 ± 690* 11.3 ± 1.2 
III. Lymphocytes 
Acute injection 3380 ± 310 8.2 ± 0.9 
Chronical injec­
tion 
4910 ± 530* 11.5 + 1.4 
* P < 0.05 as compared to acute injection group. 
The effect of phenibut and buspirone on 003 BD 
receptors in rat blood platelets. The effect of 
two nonbenzodiazepine tranquilizers on blood pla­
telet <a)j BD receptors was studied to find out if 
these compounds have any effects per se table 4). 
It was found that in vivo administration of phenibut 
(100 mg/kg) had a tendency to lower and buspirone 
(5 mg/kg) to enhance the number of -*H-Ro 5-4864 
binding sites. In addition to that only phenibut 
significantly increased the affinity for the ligand. 
In this study the calculations of the apparent number 
of binding sites were made paralell either per mg 
of protein or 108 platelets. Naturally, the values 
received were different but the tendencies observed 
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were similar. This and other similar results en­
couraged us to present the binding site data only 
per mg of protein (table 4). 
Table 4 
The effect of phenibut (100 mg/kg) and buspirone 
(5 mg/kg) pretreatment on benzodiazepine re­
ceptors in rat blood platelets. Зц-Ro 5-4864 was 
used to label benzodiazepine binding sites. 
The data expressed are mean ± S.E.M. of at least 
three indipendent experiments each carried out in 
triplicate. 
Experimental 
group mg/kg 
3h-Ro 5-4864 binding 
Bmax KD (nM) 
Saline 6102 ± 870 fmol/mg 
1269 ± 181 fmol/108 
cells 
10.7 ±0.9 
Phenibut 100 5531 ± 613 fmol/mg 
1027 ± 112 fmol/108 
cells 
7.1 ± 1.2* 
Buspirone 7471 ± 892 fmol/mg 
1544 ± 185 fmol/108 
cells 
13.1 ± 1.4 
* P < 0.05 as compared to saline controls. 
The effect of phenibut and buspirone pretreatment 
on swimming stress induced changes of g*j$ BD receptors 
in rat blood platelets and lymphocytes. The pre­
treatment of rats with phenibut (100 mg/kg) ef­
fectively counteracted the swimming stress caused 
changes of ^h-Ro 5-4864 binding on platelets and on 
lymphocytes (table 5). Lower doses of phenibut (25-50 
mg/kg) were almost without effect. Buspirone (5 
mg/кй) did not eliminate the stress induced changes 
of 3h-Ro 5-4864 binding on platelets but like 
phenibut counteracted the effect of stress on 
lymphocytes (table 5). 
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Table 5 
The effect of phenibut (100 mg/kg) and buspirone 
(5 mg/kg) pretreatment on swimming stress induced 
changes of шд benzodiazepine receptors in rat 
blood platelets and lymphocytes. Зд-Ro 5-4864 was 
used to label benzodiazepine receptors on blood 
cells. The data expressed are mean ± S.E.M. of at 
least three indipendent experiments each carried 
out in triplicate. 
Experimental 
group, mg/kg 
3h-Ro 5-4864 binding 
Bmax (mg/prot) KD (nM) 
I. Platelets 
Control 6312 ± 532 13.1 ± 0. 9 
Swimming stress 9578 ± 1012* 15.8 ± 1.6 
Swimming stress + 
Phenibut 100 
7038 ± 843 12.4 ± 1.3 
Swimming stress + 
Buspirone 5 
10109 ± 1434 14.3 ± 1.5 
II. Lymphocytes 
Control 4987 ± 632 10.1 ± 1.1 
Swimming stress 8434 ± 911* 12.8 ± 1.4 
Swimming stress + 
Phenibut 100 
611 ± 1013 11.5 ± 1.2 
Swimming stress + 
Buspirone 
6494 ± 834 13.2 ± 1.5 
* P < 0.05 as compared to control group. 
Discussion 
After various stressful situations both the 
increase [15] and decrease [14] of the number of 
central BD receptors has been reported. Most BDs 
used so for are nonselective ligands for the central 
and (A>3 (in literature often referred to as BDt 
and BDg respectively) BD receptors. Several ligands 
with nonbenzodiazepine chemical structure (CL 
218872, some betacarbolines, CGS 8216 and Zolpidem) 
have selectivity for ojj receptor subtype. The role 
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2*  
of сл^ and ca£ BD receptors in the neurochemistry of 
stress has not been comparatively studied. The effect 
of stress on cajj (peripheral-type) BD receptors has 
also been poorly studied. However, recently it has 
been shown that foot shock can decrease the number 
of Зн-Flunitrazepam binding sites in rat kidneys 
and adrenals [9]. This finding is in agreement with 
our results demonstrating that foot shock lowers 
the number of ^ н-Diazepam binding sites in rat blood 
platelets. This finding of ours is supported by the 
data showing that in man the binding capacity of 
the BD binding sites in the platelets of anxious 
patients has been shown to be reduced in comparison 
to normal controls [22] . However, in other two models 
of stress (forced swimming and chronical injection) 
the number of ^ H-Ro 5-4864 binding sites on platelets 
and lymphocytes was increased. Different ligands 
used in these studies cannot be the reason of the 
discrpancy. Similar changes in binding character­
istics after swimming stress were obtained when 
blood platelets were labeled with ^H-Diazepam 
(unpublished data). It is possible that different 
models of stress can induce different neurochemical 
changes. 
The mechanism involved in the stress induced 
changes of 005 BD receptors on blood cells is difficult 
to explain. In contrary to the central-type BD 
recognition sites ca>j BD receptors are not modulated 
by GABA or chloride ions in vitro [13]. However, it 
should be mentioned that the regulation of central 
(caj^ + caj£) and 0J5 BD receptors in several peripheral 
organs seems to be similar after in vivo pretreatment 
with GABA agonists [16, 17]. Moreover, recently we 
have demonstrated that several models of stress 
(foot shock, naive animals in comparison to hand­
ling-habituated animals etc.) cause similar changes 
both in central (cerebral cortex) and in 0J5 (kidneys 
and adrenals) BD receptors [9, 10]. It has been also 
reported that an inescapable tail shock produces a 
reduction of 3H-Ro 5-4864 binding sites in rat heart 
and kidney but not in CNS [6]. The localization of 
relatively high concentrations of UJ3 BD receptors 
in the pituitary and adrenals [5] may indicate that 
these recognition sites are involved in the neu­
roendocrinological regulation of emotional beha­
vior. The existence of at least one common endogenous 
modulator or endogenous ligand for all BD recognition 
sites may be suggested. Imidazopyridine alpidem, a 
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new BD receptor 1 igand, possesses rather similar 
affinity for the ^H-Diazepam binding site in the 
cerebellar cortex and -^H-Ro 4-4864 binding site in 
the kidney [11]. Many older generation BD (diazepam, 
flunitrazepam etc.) receptor ligands have also 
rather poor selectivities for <л^, cx^ and BD 
receptors. DBI/(diazepam binding inhibitor) is a 
proposed endogenous ligand peptide for central BD 
receptors. Interestingly, the DBI/mRNA is expressed 
not only in CNS neurons, but also in glial cells, 
liver, kidney and heart [8]. 
In the present study it was demonstrated that 
the pretreatment of rats with phenibut increased 
the affinity of ^H-Ro 5-4864 binding in rat blood 
platelets and effectively attenuated the elevation 
of maximum binding caused by swimming stress. It 
has been reported that the rise of serum prolactin 
levels caused either by swimming, immobilization, 
ether or cold stress was inhibited by pretreatment 
of rats with baclofen [4]. Phenibut, a drug 
structurally closely related to baclofen, is a weak 
GABAg receptor agonist [16]. Both САВАд and GABAg 
receptor agonists increase the affinity of 
^H-Flunitrazepam binding not only in cerebral cortex 
but also in kidneys [18] . Although these data support 
the findings of the current study the mechanism by 
which GABA receptor agonists can modulate BD 
receptors remains unknown. 
Buspirone pretreatment had only a tendency to 
enhance the number of cxg binding sites in rat blood 
platelets. Recently it was demonstrated that i n  v i vo  
buspirone in a dose related manner increases in v i vo  
labelling of central BD receptors with ^ h-Ro 15-1788 
[7]. However, this effect of buspirone seems to be 
unspecif ic because neuroleptic drugs and apomorphine 
also caused similar changes of the in vivo ^h-Ro 
15-1788 binding. 
Contrary to the phenibut buspirone pretreatment 
of animals counteracted the stress induced changes 
of txg BD receptors only on lymphocytes. Buspirone 
is also known to lower increased corticosterone and 
prolactin levels in stressed rats [21]. It may be 
suggested that the stress-protective effect of 
phenibut and buspirone on the level of blood cell 
ujg BD receptors is an indirect one, probably mediated 
through hormonal changes caused by these drugs. 
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Two main conclusions can be made from the studies 
carried out here. First, it is possible to assume 
that the number of coj BD receptors in rat blood 
platelets and lymphocytes is enhanced or lowered 
depending on the model of stress used. The stress 
induced changes of ca>j  BD receptors seem to be similar 
to those recorded in central BD receptors. Therefore 
the possibility to use cx^ BD receptors on blood 
cells as markers of the functional activity of 
central BD receptors may be suggested and further 
studies in this direction recommended. Secondly, 
the nonbenzodiazepine tranquilizers phenibut and 
buspirone, seem to have stressprotective action on 
the level of blood cell ca> j  BD receptors. However, 
further studies to establish the role and function 
of CAjg BD receptors in the neurochemical mechanisms 
involved in stress are necessary. 
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PERIPHERAL-TYPE BENZODIAZEPINE BINDING 
SITES ON RAT BLOOD PLATELETS AND 
LYMPHOCYTES: EFFECT OF IN VIVO 
ADMINISTRATION OF GABA ERGIC DRUGS 
A. Adojaan and L. Rägo 
Department of Pharmacology, Tartu University 
Abstract 
I n  v i t r o  GABA mimetics do not alter the binding 
characteristics of peripheral-type benzodiazepine 
(BZ) binding site ligands. The effect of i n  v i v o  
administration of muscimol, dipropylacetate and 
phenibut on blood cell peripheral-type BZ binding 
sites in rat was examined. Intact blood platelets 
and lymphocytes, labelled either by ^ H-Ro 5-4864 or 
Зн-Diazepam, were used in this study. Interestingly, 
not only muscimol, а САВАд receptors agonists, but 
also dipropyl-acetate and phenibut increased the 
affinity of BZ recognition sites on both types of 
blood cells studied. The number of BZ binding sites 
on blood cells was unaffected by in vivo pretreatment 
with the GABA-ergic drugs. The possible mechanism 
of in vivo modulation of peripheral-type BZ binding 
sites on blood cells by GABA-ergic drugs is dis­
cussed . 
Introduction 
The central-type benzodiazepine (BZ) binding 
site, often referred to as the BZ receptor, is an 
integral part of the САВАд receptor-chloride channel 
complex in the mammalian CNS [1]. Specific high 
affinity binding sites for benzodiazepines exist 
also in a variety of peripheral organs (adrenals, 
kidney, heart, lung etc) and on blood platelets [2], 
lymphocystes [3] and granulocytes [4]. It has become 
clear that the pharmacology and physiology of these 
two types of BZ binding sites is quite distinct (for 
review see 5). 
Several lines of evidence demonstrating that 
classical САВАд receptor agonists enhance the af­
finity of benzodiazepines for central-type benzo­
diazepine recognition sites while diazepam increases 
the density of the low affinity GABA binding sites 
indicate the existence of coupling between САВАд and 
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benzodiazepine receptors [1]. In contrast to 
central-type BZ binding sites peripheral-type BZ 
binding sites are not modulated by GABA or chloride 
ions in vitro [6, 7]. However, recently we have 
found that the in vivo pretreatment of animals with 
САВАд and GABAg agonists is capable to modulate BZ 
binding sites in several peripheral organs as well 
[8, 9]. 
The aim of the present stur'- was to examine the 
action of in vivo administration of several GABA 
mimetic drugs on blood cell peripheral-type BZ sites 
in rat. As the result of this study we present 
evidence indicating that BZ recognition sites on 
intact blood platelets and lymphocytes are regulated 
similarly to CNS BZ receptors by in vivo pretreatment 
with GABA-mimetic drugs. 
Materials and methods 
Animals and drugs. Male albino laboratory rats 
weighing 230-260 g of body weight (from Rappolovo 
Farm, Leningrad) were used. The animals were 
maintained on food and water ad libitum at 20 ± 1 
°C on a reversed lighting cycle with lights off from 
2000 to 0800. Phenibut (ß-pheny1-Gaba, Olaine 
Pharmaceuticals, Latvia), muscimol (Research Bio-
chemicals Inc. , Wayland, U.S.A.) and dipropylacetate 
(sodium valproate, Orion Pharmaceutica, Espoo, 
Finland) were dissolved in saline. The drugs were 
injected in a volume of 1 ml per kg intraperitoneally 
50 min prior to decapitation. 
In vitro bindings studies. After decapitation 
the trunk blood of each rat was collected into a 
plastic tube containing 0.5 ml of acid citrate 
dextrose (ACD) anticoagulant. Lymphocytes were 
isolated according to the method of Boyum [10] using 
the Ficoll-Pague gradient and washed twice before 
the binding experiment. Platelets were obtained from 
platelet-rich plasma by centrifugation. The pooled 
blood cells from at least 8 animals were used for 
each binding assay. 3H-Diazepam (spec. act. 82 
Ci.mmol) and -^H-Ro 5-4964 (spec. act. 84 Ci/mmol, 
both Amersham Radiochemicals, England) were used in 
eight different concentrations (0.5 - 34 nM and 0.5 
- 24 nM respectively) for labelling peripheral-type 
BZ binding sites on blood platelets or lymphocytes. 
Unlabelled Ro 5-4864 (Hoffman - La Roche, Basel, 
Switzerland) was used to determine nonspecific 
binding. The binding experiments were performed in 
18 
a total volume of 125 |_il during 30 min at 0 С; all 
binding experiments were carried out in a modified 
Hanks solution (pH 7.3). Intact blood platelets and 
lymphocytes were used throughout these studies. 
After incubation of the tubes containing either 
lymphocyte or platelet suspension the reaction was 
stopped by rapid filtration over Whatman GF/B 
filters. The filters were washed with 3 x 3 ml of 
ice cold buffer. Specific binding was calculated by 
subtracting the nonspecific from total binding at 
each given radioactivity concentration. Protein was 
measured by the Lowry et al. [11] method. 
Calculations and statistics. Maximum binding 
(B m a x) and affinity constants (KD) were calculated 
using the Scathard plot analysis. The Scathard plots 
were computed using linear regression program. For 
the data presented, only the plots with a correlation 
coefficent of 0.85 or more were accepted. 
The significance of the differences between the 
results was tested using Student's t-test; p < 0.05 
was considered significant. 
Results 
The effect of GABA agonists in vitro on 
peripheral-type BZ binding sites on intact blood 
platelets. 
The binding studies were carried out in a modified 
Hanks oSolution or TRIS-HC1 (pH = 7.3) during 30 min 
at 0 °C or during 15 min at 37 °C. In vitro GABA (1 
- 1000 MM), muscimol (0.1 - 500 цМ) and phenibut (10 
- 1000 цМ) did not alter -^H-Diazepam binding with 
intact blood platelets (data not shown). 
The effect of in vivo administration of GABA 
agonists on Зн-Diazepam and 3jj_r0 5-4864 binding 
with intact blood platelets and lymphocytes. 
In these studies muscimol (1.5 mg/kg), di-
propylacetate (75 - 150 mg/kg) and phenibut 9100 
mg/kg) were used in doses that were previously shown 
to act on Зн-flunittazepam binding in rat cerebral 
cortex and kidneys. The lower doses of these com­
pounds did not produce statistically significant 
increase in the affinity for the ligand, neither in 
CNS nor in peripheral organs (data not shown, see 
also 14). 
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Muscimol (1.5 mg/kg) i n  v i v o  increased the af­
finity of ^h-Ro 5-4864 binding both on platelets 
and lymphocytes (tables 1 and 2). Phenibut sig­
nificant ly increased only 3H-Ro 5-4864 binding on 
blood platelets. Dipropylacetate, an indirect GABA 
agonist, increased the affinity of ^H-Diazepam 
binding on blood platelets and lymphocytes similarly 
to muscimol (table 3). 
Table 1 
The effect of in vivo administration of muscimol 
(1.5 mg/kg), phenibut 100 mg/kg) and buspirone (5 
mg/kg) on Зн-Diazepam binding on intact blood 
platelets and lymphocytes in rats. The data ex­
pressed are ± S.E.M. of at least 3 indipendent 
experiments each carried out in triplicate. 
Experimental 
group, 
mg/kg 
Зн-Diazepam binding 
Bmax (fmol/mg 
prot.) 
K D  (nm) 
I. Platelete 
Saline 610 ± 80 14.8 ± 1.2 
Muscimol 1.5 580 ± 60 12.1 ± 1.1 
II. Lymphocytes 
Saline 510 ± 30 12.1 ± 0.9 
Muscumol 1.5 440 ± 60 8.9 ± 0.8* 
Saline 480 ± 40 16.3 ± 1.4 
Phenibut 390 ± 80 19.1 ± 1.8 
* P < 0.05 as compared to saline treated animals 
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Table 2 
The effect of in vivo administration of muscimol 
(1.5 mg/kg), phenibut (100 mg/kg) and buspirone 
(5 mg/kg) on 3h-Ro 5-4864 binding on intact blood 
platelets and lymphocytes in rats. The data ex­
pressed are mean ± S.E.M. of at least 3 indepen­
dent experiments each carried out in triplicate. 
Experimental 
group, 
mg/kg 
3h-Ro 5-4864 binding 
Bmax (fmol/mg 
prot.) 
KD (nM) 
I. Platelet 
Saline 6870 ± 530 fo H- О
 
00
 
Muscimol 5790 ± 810 7.5 ± 0.6* 
Saline 6910 ± 720 о
 
H-
О
 
Phenibut 5030 ± 870 7.1 ± 0.8* 
II. Lymphocytes 
Saline 4870 ± 660 9.4 ± 0.8 
Muscimol 4250 ± 740 6.9 ± 1.1 
* P < 0.05 as compared to saline treated animals 
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Table 3 
The effect of in vitro administration of dipropy-
lacetate (DPA; 150 mg/kg) on ^ H-Diazepam binding 
on intact blood platelets and lymphocytes in 
rats. The data expressed are mean ± S.E.M. of at 
least 3 indipendent experiments each carried out 
in triplicate. 
Experimental 
group, 
mg/kg 
Зн-Diazepam binding 
Bmax (fmol/mg 
prot.) 
KD (nM) 
I. Platelete 
Saline 490 ± 70 16.3 ± 1.2 
DPA 75 410 ± 110 13.4 ± 1.5 
DPA 150 380 ± 60 10.7 ± 1.6* 
II. Lymphocytes 
Saline 380 ± 50 13.4 ± 1.3 
DPA 7 5 390 ± 80 12.3 ± 1.8 
DPA 150 320 ± 40 9.1 ± 1.1* 
* P < 0.05 as compared to saline treated control 
animals 
Discussion 
Phenibut, a structural analogue of baclofen, has 
been demonstrated do displace Зц-gabA from GABAg 
binding sites and is considered to be a GABAg agonist 
[12]. Dipropylacetate (sodium valproate) raises the 
synaptic concentrations of GABA by slowing its 
metabolic degradation [13] and would thus be an 
indirect GABA agonist. 
In our previous experiments it has been shown 
that muscimol, a GABA д receptor agonist, pre­
treatment significantly increased the affinity of 
BZ binding sites not only in cerebral cortex but 
also in kidneys. Similar changes were obtained also 
with (-)baclofen, a stereoselective GABAg agonist. 
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In the present study it was demonstrated that 
muscimol (1.5 mg/kg) increased the affinity for the 
ligand both on blood platelets and on lymphocytes. 
Phenibut (100 mg/kg) increased only the affinity of 
3h-Ro 5-4864 binding on platelets whereas di-
propylacetate (from 150 mg/kg) effectively lowered 
the Kq values of ^H-Diazepam binding in both cell 
types. 
Accordings to these results it is possible to 
conclude that both САВАд and GABAg type agonists can 
increase in vivo the affinity of peripheral-type BZ 
binding sites on blood cells. This in vivo action 
of GABA agonists is difficult to explain. Several 
studies have revealed that there are no GABA binding 
sites, no GABA-ergic regulation, no barbiturate 
regulation and no "S-TBPS binding present in the 
purified peripheral-type DZ receptors [7]. However, 
such kind of experiments have not been actually 
carried out on blood cells. In spits of this our 
experiments showing that GABA and muscimol i n  v i t ro  
cannot modulate BZ ligand binding to its recognition 
sites on platelets asserts that the peripheral-type 
BZ binding sites on blood cells are not coupled to 
GABA receptor gated chloride channel. Although the 
problem of endogenous ligand for BZ receptors is 
still obscure, our present data seem to support the 
idea that there should be at least one common en­
dogenous modulator (ligand?) for both types of BZ 
receptors. It has been shown that DBI (a neuropeptide 
with diazepam binding inhibiting properties) m RNA 
is expressed not only in neurons but also in many 
peripheral organs where peripheral-type BZ binding 
sites are present [15, 16]. Recently it was dem­
onstrated that physiologically active porphyrines 
are very potent ligands for peripheral-type BZ 
binding sites in several species and organs [17]. 
However, the porphyrines are about 1000 times less 
potent at central-type BZ receptors [17]. 
On the other hand, if to consider that naive 
animals are always stressed by decapitation pro­
cedure [18] then the effect of GABA agonists on 
peripheral-type BZ binding sites may be a 
stress-protective action without any direct in­
teraction with them. However, various stressful 
situations seem to change mainly BZ receptor density 
[19, 20] but in our studies GABA agonists increased 
the affinity. 
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In conclusion, the i n  v i v o  pretreatment of rats 
with GABA agonists increased the affinity of 
peripheral-type BZ binding sites on blood platelets 
and lymphocytes. The mechanism of this action of 
GABA agonists remains to be elucidated. 
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Abstract 
In experiments on male rats chronic diazepam (10 
mg/kg/day; i.p., 30 days) treatment induced spon­
taneous abstinence 48-72 hours after termination of 
the drug treatment. Administration of benzodiazepine 
receptor antagonist CGS 8216 (5 mg/kg; i.p.) to 
diazepam withdrawn animals induced an additional 
increase in the severity of benzodiazepine symptoms. 
Calcium channel antagonists verapamil (10 mg/kg) 
and nifedipine (5 and 10 mg/kg) administered 30 min 
prior to CGS 8216 suppressed the signs of abstinence. 
In animals withdrawn from chronic diazepam decreased 
/^н/ Nitrendipine binding and increased 4 5Ca 2 +  uptake 
by depolarized synaptosomoses were observed. An 
increased synaptosomal 4 5Ca 2 +  uptake was antagonized 
by in vitro addition of diazepam (1 цМ) or verapamil 
(1 pM) . In control animals these drugs did not change 
synaptosomal 4 5Ca 2 +  uptake. It is proposed that 
chronic diazepam treatment induced the activation 
of voltage sensitive calcium channels and intra-
neuronal calcium accumulation which can be con­
tributed to the development of abstinence signs. 
Introduction 
Because of very widespread use of benzodiazepines 
in medical practice, the dependence - producing 
liability of these drugs and the severity of symptoms 
associated with their withdrawal are the concerns 
of considerable importance. A number of withdrawal 
symptoms resulting from an abrupt cessation of 
benzodiazepines in laboratory animals have been 
reported [2, 3, 10, 12, 17, 18]. The abstinence 
syndrome in the laboratory animals chronica 1ly 
treated with benzodiazepines might also be induced 
by the administration of benzodiazepine receptor 
2 7  
4 *  
antagonists Ro 15-1788 [13], or CGS 8216 [24, 25]. 
The extensive experimental evidences suggested that 
the structural basis of the action of benzodiazepines 
is represented by a hypothetical 
GABA-benzodiazepine-barbiturate-Cl ionophore re­
ceptor complex (for review see 5, 21]. Benzo­
diazepines interacting with benzodiazepine receptor 
enhance the affinity of GABA receptor which results 
in the opening of chloride channels and consequently, 
in an increase of the membrane conductance for 
chloride ions [5]. There is some evidences suggesting 
that the abnormalities of GBB complex develop in 
the course of chronic benzodiazepine treatment and 
these abnormalities might be contributed to the 
development of benzodiazepine withdrawal syndrome. 
Thus, a decrease in a number of benzodiazepine 
receptors and diminution of the stimulatory effect 
of GABA benzodiazepine binding has been found in 
animals withdrawn from chronic benzodiazepine 
treatment [4, 16]. These changes were accompanied 
with the increased chloride conductance in response 
to GABA [23]. 
In addition, some evidence has suggested that 
alterations in calcium conductance might be involved 
in the action of benzodiazepines and consequently 
in the development of withdrawal syndrome after 
chronic benzodiazepine treatment. In our previous 
preliminary study, the organic calcium channel 
antagonists abolished the signs of benzodiazepine 
abstinence precipitated in rats by benzodiazepine 
receptor antagonist CGS 8216. The effect of acute 
benzodiazepines on Ca^+ flux in neuronal tissue 
remains, however, controversal. There have been 
reports that benzodiazepines enhance calcium entry 
into synaptosomal preparations and nifedipine 
blocked this effect [14]. Calcium channel abtago-
nists were also effective against abstinence induced 
by morphine and ethanol [1, 9] / Chronic morphine 
treatment results in an increased [^H]nitrendipine 
binding and accumulation of intrasynaptosomal Ca^ + 
[19, 22]. These observations promoted the further 
examination of the role of voltage sensitive calcium 
channels in the withdrawal syndrome following 
chronic benzodiazepine treatment. Also, the effects 
of calcium channel antagonists on the signs of 
benzodiazepine was further studied. 
28 
Materials and methods 
Animals and drug treatment. Male Wistar rats with 
initial weight 200-230 g were housed in groups of 
8-10 animals in standard vivarium conditions. The 
groups of animals were administered i.p. either 
diazepam (10 mg/kg) or 0.9 % NaCl saline once daily 
for 30 days. At various times after saline or diazepam 
withdrawal animals were sacrificed by the cervical 
dislocation and the brains were taken for the as­
sessment of 45ca2+uptake or [^H]nitrendipine 
binding. Remaining groups of animals were taken for 
behavioral study. The signs of precipitated ab­
stinence were assessed. 
Behavioral study. Animals chronically treated 
with diazepam were withdrawn for 48-72 hrs and then 
randomly divided into groups of 8-10 animals, one 
of which was administered i.p. benzodiazepine re­
ceptor antagonist CGS 8216 (2-phenylpyrazolo 
[4, 3- ] quinoli.n-3 (5H)-one, 5 mg/kg, i.p. or CGS 8216 
in combination with calcium channel antagonists and 
the signs of abstinence were checked within 30 min 
after CGS 8216 administration. The most pronounced 
signs of abstinence were head twitches and myoclonic 
jerks of forepaws, therefore the number of these 
behavioral signs was counted within an observation 
period. 
[Зн]Nitrendipine binding. The preparation of 
membranes and [^H]nitrendipine binding were per­
formed according to the method of Marangos et al. 
[11]. The rat forebrains were homogenized in 25 
volumes (w/v) of 50 mM TRIS HCl buffer (pH = 7.4 at 
25 C). The resulting homogenate was centrifuged at 
1000 g for 10 minutes. The supernatant was recen-
trifuged again at 30 000 g for 30 min. The resulting 
pellet was resuspended in 200 volumes (w/v) of TRIS 
HCl buffer. The aliquots of membrane preparation 
containing approximately 0.2 mg of membrane protein, 
were incubated in the dark with various concen­
trations of o[^H]nitrendipine (0.025 - 1.0 nM) for 
90 min at 25 °C in a total volume of 1 ml. Nonspecific 
binding was determined using 1 цМ nifedipine. Assays 
were terminated by vacuum filtration on Whatman GF/B 
filters with two 5 ml washes of ice cold buffer. 
The filters were counted in 8 ml of dioxine based 
scintillator with the counting effectiveness about 
45 %. 
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45ca2+ uptake by rat brain synaptosomes. Prep­
aration of synaptosomes and ^Ca^"1" uptake were 
performed according to the method of Mendelson et 
al. (1984) with a slight modification. The cerebral 
cortices were dissected out and homogenized in 20 t 
vol of ice-cold 0.32 M sucrose using a glass hom-
ogenizer with teflon pestle. All subsequent steps 
for isolation of synaptosomes were done at 0 - 4 
°C. The homogenated was centrifuged at 1000 g for -
10 min and the resulting supernatant was recen-
trifuged at 17 000 g for 20 min. This pellet (P2) 
was resuspended in 0.32 M sucrose at 2-4 mg/ml of 
protein with teflon pestle. The aliquots (0.050 ml) 
of this synaptosomal suspension were added to the 
glass tubes containing 0.750 ml of buffer (136 mM 
NaCl, 5.0 mM KCl, 1.3 mM MgCl2, 20 mM TRIS HCl, 11 
mM glucose, pH = 7.4) and 0.1 ml of drug solutions 
or vehicle (NaCl buffer without glucose). The tubes 
were preincubated for 20 min on ice and then for 10 
min at 37 С in a shaking water bath. The uptake 
was initiated by adding 50 pM of ^5ca2+ £n q.5 м Df 
NaCl for non-depolarized samples and in 0.5 M of 
KCl for depolarized samples. Cold CaCl2 (50 цМ) was 
added consequently. The final CaCl2 concentration 
was 100 цМ. The incubation was continued for 60 sec. 
The uptake was terminated by rapid filtration through 
GF/B filters followed by four 4 ml washings with 
ice-cold solution containing 145 mM of KCl, 1.2 mM 
of CaCl2 and 20 mM of TRIS HCl, pH = 7.4. All 
experiments were performed in triplicate. Filters 
were put in scientillation coctail and counted in 
a Beckman scintillation counter LS-6800. 
Chemicals and drugs. [3H]Nitrendipine (Psec. act. 
81. 1 Ci/mmol) was purchased from New England Nuclear 
pic., ^CaCl2 (Spec.act. 0.9 Ci/mmol) from Isotop 
(USSR). Calcium channel antagonists: nifedipine and 
verapamil were generously provided by Orion Far-
maceutica (Finland), diazepam - from La Roche (Basel, 
Switzerland), CGS 8216 was a gift from Sandoz Ltd. 
(Basel, Swutzerland). Nifedipine, diazepam and CGS 
8216 were dissolved in saline containing a few drops 
of Tween-80. Verapamil was dissolved in 0.9 % NaCl 
solution. 
Statistics. Statistical analysis was performed 
using Student's t-test for unpaired samples or 
Dunnett's test where appropriate. 
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Results 
Effect of calcium channel blockers on CGS 8216 
precipitated abstinence. Chronic treatment with 
diazepam (10 mg/kg) for 30 days followed by ad­
ministration of CGS 8216 (5 mg/kg, i.p.) produced 
increased locomotor activity, head twitches, burst 
of myoclonic jerks of forepaws, increased emotional 
reactivity, poker tail, incidents of facial clonus. 
This behavioral syndrome developed in 5-10 min after 
CGS 8216 administration and lasted for 40 min. CGS 
8216 when administered to control animals did not 
produce any behavioral abnormalities. Similar signs 
were seen in spontaneously withdrawn animals, 
however, they were less pronounced and a considerably 
lower number of animals exhibited those signs (data 
not shown). Since head twitches and myoclonic jerks 
of forepaws were the most prominent and could be 
easily measured quantitatively these signs were 
chosen for the assessment of the severity of ab­
stinence in- further experiments. Our previous 
studies [24, 25] have shown that CGS 8216 induced 
behavioral syndrome in diazepam withdrawn animals 
depended on the dose and duration of diazepam 
treatment, and was suppressed by the administration 
of diazepam. 
The effect of calcium channels' antagonists of 
the signs of CGS 8216 precipitated abstinence is 
presented in table 1. When calcium channel antag­
onists verapamil (10 mg/kg) and nifedipine (5 mg/kg 
and 10 mg/kg) were administered 30 min prior to the 
CGS 8216 treatment, the drugs effectively suppressed 
the signs of abstinence in diazepam withdrawn animals 
(Table 1). Verapamil and nifedipine in similar doses 
were also effective in suppressing the signs of 
spontaneous abstinence (data not shown). 
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Table 1 
The effect of calcium channel antagonists and 
agonists on the benzodiazepine abstinence pre­
cipitated by CGS 8216 (5 mg/kg) in rats. Drugs 
were administered i.p. 30 min before CGS 8216 ad­
ministration. Data are means ± SEM. 
Drug dose 
(mg/kg) 
N 
Abstinence signs 
Number of 
Head twitches Myoclonic 
jerks 
Control 8 6.30 ± 2.50 5.00 ± 0.8 
Verapamil 10. 0 8 0.12 ± 0.06** 0.43 ± 0.3** 
Control 7 6.70 ± 1.70 4.00 ± 1.4 
Nifedipine 5.0 8 2.90 ± 1.10 1. 10 ± 0.5** 
Control 13 8.20 ± 1.50 4.10 ± 1.0 
Nifedipine 
10. 0 
8 3.80 ± 0.70** 1.40 ± 0.5** 
- P < 0.01 (Dunnett's t-test). * - P < 0.05; ** 
[Зн]Nitrendipine binding in diazepam-withdrawn 
rats. PH]Nitrendipine bound with high affinity to 
membranes from rat forebrain. The saturation 
analysis in co-ordinates of Scatchard revealed only 
single population of binding sites with the density 
of 140 ± 20 fmol/mg protein. Chronic treatment with 
diazepam resulted in a decrease in the density of 
binding sites 48 hours after the termination of drug 
treatment, whereas binding affinity was not changed 
in comparison with control (fig. 1). 
Calcium uptake in diazepam withdrawn rats. Acute 
or chronic afministration in a dose of 10 mg/kg i.p. 
did not induce any changes in ^ ca2+ uptake in low 
K+ medium (resting synaptosomes) or in high K+ medium 
(depolarized synaptosomes) 1 hour after withdrawal. 
However, 48-72 hours after the termination of chronic 
diazepam treatment a significant increase in ^ Ca2+ 
uptake was observed (Table 2). This increase in 
uptake returned to the control level 120 
hours after the termination of chronic diazepam 
treatment. 
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Fig. 1. [3H]Nitrendipine binding to the membranes from the rat forebrain 
48 hre after chronic saline or diazepam (10 mg/kg/day; 30 days) 
treatment. The data are means ± SEM of 4 separate experiments. -
P < 0.05. 
Table 2 
45ca2+ uptake by rat brain synaptosomes in control animals and animals withdrawn 
from chronic diazepam (10 mg/kg/day, 30 days) treatment. Results presented are means 
± SEM. 
Time 
(hrs) 
after 
with­
drawal 
N 45(ja2+ uptake (nmol/mg protein/min) 
5 mM K+ 55 mM K+ Netto uptake 
Control: chronic sa­
line 
12 0.94 ± 0.08 2.14 ± 0. 16 1.21 ± 0.12 
Acute diazepam 1 4 0.96 ± 0.22 1.96 ± 0.40 1.0 ± 0.18 
Chronic diazepam 1 3 0. 73 ± 0.12 1.74 ± 0.24 1.01 ± 0.16 
24 2 1.04 ± 0.07 2.49 ± 0.14 1.46 ± 0.08 
48 4 0.84 ± 0.12 2.56 ± 0.10* 1.72 ± 0.06* 
72 5 1.21 ± 0.17 2.95 ± 0.26* 1. 74 ± 0. 11* 
120 3 0.75 ± 0.17 1.96 ± 0.22 1.21 ± 0.12 
* - P < 0.05 (Student's t-test). 
Table 3 
* Effect of diazepam on ^ 5ca2+ uptake by synaptosomes from the rat forebrain 72 hrs 
after termination of chronic saline or chronic diazepam (10 mg/kg/day, 30 days). 
Calcium uptake by rat brain synaptosomes was tested in low potassium medium (5 mM 
K+) or in high potassium medium (55 mM K+). Results represent means ± SEM. 
Group, drug concentra­
tion 
N 45ca2+ uptake (nmol/mg protein/min) 
5 mM K+ 55 mM K+ Netto uptake 
Chronic saline 12 0.94 ± 0.08 2. 14 ± 0. 16 1.21 ± 0.12 
+ diazepam 1 |jM 5 0.82 ± 0.07 1.91 ± 0.19 1. 10 ± 0.12 
10 MM 2 0.91 ± 0.27 2. 13 ± 0.25 1. 22 ± 0.17 
Chronic Diazepam 5 1.21 ± 0.17 2.95 ± 0.26* 1. 74 ± 0.11* 
+ Diazepam 1 pM 2 1. 14 ± 0.14 1.85 ± 0.11 0.7 ± 0.09* 
10 |JM 4 0. 84 ± 0.12 1.48 ± 0.14 0.64 ± 0.07** 
* - P < 0.05; ** P < 0.01 (Student's t-test). 
CHRONIC SALINE CHRONIC DIAZEPAM 
VERAPAMIL JTiM VERAPAMIL jtiM 
Fig. 2. Effect of verapamil on 45ca2+ uptake by depolarized synaptosomes 
(55 mM K+) 72 hrs after chronic saline or diazepam (10 mg/kg/day; 
30 days) treatment. The data are means ± SEM of three separate 
experiments. - P < 0.05; - P < 0.01. 
The diazepam added to the incubation medium 
containing depolarized synaptosomes in concentra­
tion 1 and 10 цМ from the brains of diazepam withdrawn 
rats prevented the increase in^ca2 + uptake, whereas 
it did not change ^ 5ca2+ uptake by synaptosomes from 
control animals (Table 3). 
Verapamil in concentration of 1 цМ did not change 
45ca2+ uptake by depolarized synaptosomes from 
control animals, but reduced an increased ^5ca2+ 
uptake by synaptosomes from diazepam withdrawn rats 
(Fig. 2). Verapamil in a concentration of 10 цМ 
decreased ^5ca2+ uptake by synaptosomes from both 
control and diazepam-withdrawn animals. 
Discussion 
A number of studies have shown that the increase 
of Ca2+ influx via voltage sensitive calcium channels 
might be involved in the development of withdrawal 
syndrome after chronic morphine [19, 22] or chronic 
alcohol [9] treatment. Calcium channel antagonists 
were effective in suppressing the abstinence signs 
induced by chronic morphine or ethanol [1, 9]. 
The results of the present study also show that 
the calcium channel antagonists verapamil and 
nifedipine are effective in the suppression of the 
signs of diazepam-induced abstinence. Similarly, 
during withdrawal from chronic diazepam treatment 
an increased Са^+ influx via voltage sensitive 
calcium channels was also observed. The increased 
influx of calcium was found within 48-72 hours which 
coincided with the peak of severity of the spon­
taneous or CGS 8216 precipitated abstinence. 
Diazepam and calcium channel antagonist verapamil 
added in vitro reduced an increased ^5ca2+ uptake 
by synaptosomes from diazepam withdrawn animals. 
Taken together these data suggest that an increase 
in Ca2+ influx via voltage sensitive channels might 
be involved in the development of diazepam withdrawal 
syndrome. However, the increase in Са^+ uptake in 
diazepam withdrawn animals was accompanied by the 
decreased of pH]nitrendipine binding. These 
dindings are difficult to explain since in the 
previous studies with morphine withdrawn animals an 
increased Ca^+ uptake by rat brain synaptosomes 
simultaneously with elevated pH]nitrendipine 
binding has been observed in these animals [19, 22]. 
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Some studies, however, suggested that pH]ni­
trendipine binds only to the closed calcium chan­
nel.The activation of channel induced a rapid fall 
in the affinity of dihydropyridine site for 
pH]nitrendipine [6]. In our experiments, however, 
only a decrease in the density of dihydropyridine 
binding sites without any changes in affinity 
constant has been observed. It might be proposed t 
that the observed decrease in the density of 
pH] nitrendipine binding sites might represent a 
compensatory reaction developing in response to an 
increased Ca^+ uptake by synaptosomes from the brain 
of diazepam withdrawn animals. In our experiments, 
diazepam added to incubation medium did not change 
^Ca^"1" uptake by synaptosomes from control animals 
but, suppressed an increased ^5ca2+ uptake by 
synaptosomes from diazepam withdrawn animals. These 
data indicate that chronic diazepam treatment may 
increase calcium channels sensitivity. This prop­
osition is further supported by the fact that 
verapamil in relatively low concentration (1 цМ) 
was able to suppress synaptosomal ^ (;a2+ uptake only 
in diazepam withdrawn animals. The accumulation of 
intrasynaptosomal calcium after diazepam withdrawal 
might alter many neuronal functions including the 
increase of intrasynaptosomal protein phosphory­
lation and amine release, which in turn might be 
involved in the appearance of the abstinence signs. 
In conclusion, our data suggest that benzodiaze-
pine-induced abstinence may have similar mechanisms 
with morphine or alcohol induced abstinence and that 
an accumulation of intraneuronal calcium may also 
be contributed for the development of abstinence 
signs in diazepam withdrawn animals. 
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CALCIUM CHANNEL ANTAGONISTS INDUCED 
YAWNING BEHAVIOUR IN RATS 
A. Zarkovsky, K. ?ereska, G. Gebers 
Molecular Pharmacology and Pharmacokinetics Re­
search Unit and Department of Pharmacology, Tartu 
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Abstract 
Calcium channel antagonist, of various chemical 
structure nifedipine, flunnarizine, verapamil and 
diltiazem after systemic administration dose de-
pendently induced yawning behaviour in rats. The 
rank order potency for these drugs = flunnarizine 
> verapamil = diltiazem. This effect seems mediated 
centrally, since flunarizine and verapamil induced 
yawning after intracerebroventricular as well as 
after systemic administrations. Combined treatment 
of calcium channel antagonists with dopamine re­
ceptor agonists apomorphine and quinpirole or 
muscarinic cholinoceptor agonist pilocarpine re­
sulted in an enhancement of yawning behaviour. 
Dopamine D1 and D2 receptor subtypes' antagonists 
sulpiride, haloperidol and SCH 23 390 or muscarinic 
cholinoceptor antagonist scopolamine dose de-
pendetly inhibited nifedipine-induced yawning. 
Also, phosphodiesterase inhibitor milrinone su-
pressed nifedipineinduced yawning. It is proposed 
that calcium flux via voltage gated channels may be 
involved in the expression of yawning behaviour. 
Introduction 
Organic calcium channel antagonists represent a 
large number of compounds of various chemical 
structure affecting calcium movement across mem­
branes via voltage dependent calcium channels. The 
pharmacological actions of these drugs on the 
cardiovascular system are extensively studied since 
they have beneficial effects in the treatment of 
several cardiovascular disorders. However, less is 
know about central effects of calcium channel an­
tagonists. Recently, specific calcium channel an­
tagonists binding sites have been shown to be present 
in the central nervous system [5, 18, 23]. 
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The functional sequences of these sites occu­
pation remained unknown because in neuronal tissues 
it has been difficult to demonstrate the functional 
effect of organic calcium channel antagonists, since 
in pharmacologically meaningful concentrations 
these drugs have no marked effect on the calcium 
mediated processes [21, 29] . However, recent be­
havioral studies on laboratory animals have shown, 
that calcium channel antagonists may possess some 
psychopharmaсоlogical actions independently of 
their cardiovascular effects. It has been reported 
that dihydropyridines reduced immobility time in 
the mouse behavioral dispair test [20], antagonized 
reserpine induced catalepsy [11], prevented the 
behavioral manifestations of the morphine abstinence 
in rat [1, 30] and benzodiazepine abstinence in rat 
[30]. In addition to that, some calcium channel 
blockers possessed anticonvulsive activities in 
several models of epilepsy [3, 28, 19]. 
In the present study we report that calcium 
channel antagonists in addition to their knowi) 
psychopharmaсоlogical effects induce yawning be­
haviour in rats. Since yawning is a readily 
quantified behavioral response which can be induced 
by various agents including dopamine receptor 
agonists and muscarinic cholinceptor agonists the 
effect of drugs interacting with these receptors on 
calcium channel antagonists induced yawning was 
studied. 
Materials and method 
Animals. Male Wistar rats weighing 250-300 g were 
used. They were housed 8 per cage in a well il­
luminated room at an ambient temperature of 21-22 
С and kept on a standard diet and tap water ad 
libitum. All experiments were carried out between 
3 p.m. and 8 p.m. in a diffiusely illuminated room. 
Behavioral testing. Testing was conducted in the 
individual plexiglaas boxes of 20 x 20 x 20 cm. The 
animals were habituated to test cages for 30 min 
prior to drug injection. The number of yawning 
episodes was counted during a 60 min test using hand 
held counter. 
Intracerebroventricular injections. Rats were 
anesthetized with ethyl ether. After incision of 
the skin of the head, a hole was made in the skull 
at the following coordinates: L = 1.5 mm, 2 mm 
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posterior to bregma. Six hours later, intracere-
broventricular injections (25 [0.1) were made free­
hand in the right lateral ventricle with a 
microsyringe connected to a needle whose medial part 
of the bevel protruded only 5 mm from a guard limiting 
its penetration into the brain. 
Drugs. The drugs used were: nifedipine, flun­
nar izine HCl, verapamil HCl and diltiazem HCl (all 
were generously donated by Orion Farmaceutica, 
Finland), milrirone was a gift of the Institute of 
Organic Syntheris (Riga, USSR). quinpirole HCl (Ely 
Lilly, Indianopolis, USA), apomorphine HCl, pilo­
carpine HCl (USSR), 2-(+)-8-chloro-2,3,4,5-tetra-
hydro-3-methyl-5-phenyl-lH-3-benzazepine-7-ol he­
rn i ma 1 e а с e (SCH 23 390; Schering, New Jersey, USA), 
sulpiride (Commercial Ampoules, de Lagrange, Paris, 
France), haloperidol (Janssen Farmaceutica, Beerse, 
Belgium), scopolamine (USSR). 
Nifedipine, flunnarizine, diltiazem and SCH 
23 390 were suspended in solution containing 1% of 
Tween-80, haloperidol was dissolved in a minimal 
volume of glacial acetic acid and the solution was 
then brought to pH = 5.0 with 0. 1 N NaOH and finally 
diluted with 0.9% NaCl solution. Apomorphine and 
quinpirole were dissolved in 0.9% NaCl solution 
containing 0.05% ascorbic acid to prevent oxydation. 
All other drugs were dissolved in 0. 9% NaCl solution. 
All drug solutions and suspensions were prepared 
freshly before the experiments. Apomorphine and 
quinpirole were administered subcutaneously. All 
other drugs - intraperitoneally. 
Statistical analysis. Individual group differ­
ences were determined by appropriate Dunnett's t-
test. A probability of P < 0.05 was regarded as 
significant. 
Results 
Effect of clacium channel antagonists after i.p. 
administration. Calcium channel blockers of various 
chemical structure: nifedipine, flunnarizine, 
verapamil, diltiazem after i.p. administration to 
rats elicited yawning behaviour (Fig. 1). This effect 
was dosedependent, with maximalum effect at the dose 
of 10~20 mg/kg. However, the dose response curves 
were relatively shallow. No further increase in the 
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Fig. 1. Doee responses of yawning induced by calcium channel antagoniste 
after their i.p. administration. Yawns were counted for 60 min 
and 10 min after nifedipine and flunnarizine. Each column 
represents mean ± SEM of 8 animals. * - P < 0.05; ** P < 0.01 
(Dunnett's test). 
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Table 1 
Effect of Combined treatment of dopamine receptor 
agonists and muscarinic cholinoceptor agonist pi­
locarpine with calcium channel antagonists on 
yawning behaviour in rats. Data are means ± SEM 
of groups from 8-10 animals. 
Drug, dose 
(mg/kg) 
Number of yawns in 60 min 
Apomorphine 
(0.1 mg/kg) 
Quinpirole 
(0.01 
mg/kg) 
Pilocarpine 
(1.0 mg/kg) 
Control: 
saline 12.5 ± 0.5 11.0 ± 2.0 15.0 ± 3.6 
Nifedipine 
10.0 
38.0±3.4** 36.0±6.0** 27.5 ± 5.0* 
Flunnarizine 
10.0 
27.0 ± 3.1* NT 23.8 ± 4.6* 
Verapamil 
10.0 
21.5 ± 2.0* 14.0 ± 5.0 NT 
Diltiazem 
10.0 
22.4 ± 4.1* NT 16.0 * 4.0 
* - P < 0.05: ** - P < 0.01 (Dunnett's test). NT -
not tested. 
Milrinone which is known as potent adenosine!, 
receptor antagonist and adenylate cyclase activator 
and phospodiesterase activity inhibitor [22] in­
hibited yawning. 
Discussion 
The results obtained in the present study indicate 
that calcium channel antagonists of various chemical 
ctructure and somewhat different mechanism of action 
at calcium channel elicit yawning behaviour in rats. 
This effect of calcium channel antagonists seems to 
be mediated centrally since this effect could be 
induced after intracerebroventricular as well as 
after intraperitoneal administration of these drugs. 
Among the calcium channel antagonists used in the 
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present study nifedipine and flunnarizine were the 
most potent whereas verapamil and diltiazem produced 
a considerably weaker effect on yawning behaviour. 
These data are consistent with those obtained by 
the other authors who showed that flunnarizine and 
dihydropyridines were more powerful against sound 
induced convulsions in mice than diltiazem or 
verapamil [2]. 
Binding studies revealed that dihydropyridines 
and flunarizine are potent competitive displacers 
of pH]nitrendipine from its binding sites, whereas 
verapamil and diltiazem affect pH]nitrendipine 
binding via an allosteric mechanism [5, 18, 7, 23]. 
On the basis of these findings it may be proposed 
that dihydropyridine binding sites may have a more 
important role in the regulation of yawning be­
haviour . 
Also, differences in the pharmacokinetics of 
various calcium channel antagonists should probably 
be taken into consideration. Thus, dihydropyridines 
more readily penetrate blood-brains barrier than 
verapamil [ 14, 24] that also may contribute to their 
properties of inducing more intense yawning be­
haviour . 
A number of investigations have pointed out the 
involvement of dopamine receptors and muscarinic 
acetylcholine receptors in the regulation of yawning 
[27, 12, 10]. In confirmation to the previous studies 
dopamine D2 receptor agonist quinpirole or mixed 
D1/D2 receptor agonist apomorfine and muscarinic 
cholinoceptor agonist pilocarpine induced intence 
yawning in rats. The combined treatment of nifedipine 
with quinpirole, apomorfine or pilocarpine resulted 
in an enhancement of yawning. This enhancement, 
however, was additive rather than potentiating. The 
D2 receptor antagonist sulpiride and haloperidol as 
well as muscarinic cholinoceptor antagonist sco­
polamine were highly effective against nifedipi-
ne-induced yawnings. These data indicate the 
existence of interaction between dihydropyridine 
binding sites and dopamine and muscarine receptors 
in the regulation of yawning behaviour. Some recent 
evidence suggested the existence of direct inter­
action of calcium channel antagonists with dopa­
minergic and cholinergic systems. Organic calcium 
channel antagonists inhibit the specific binding of 
pH]spiperone to D2 receptor [4]. Similarly, mus­
carinic receptor binding in the channel also in­
hibited by calcium [6]. However, it is unlikely that 
direct interaction of calcium channel antagonists 
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with these receptors is contributed to the appearance 
of yawnings, because the most powerful drugs in 
induction of yawning nifedipine and flunnarizine 
were rather weak or ineffective inhibitors of 
binding to dopamine or muscarinic receptors. In 
contrast, verapamil potently inhibited binding but 
possessed a rather weak ability to induce yawning. 
The previous studies have shown that dopamine 
receptor agonist quinpirole in nanomolar concen­
trations is able to decrease the level of intra-
neuronal free calcium concentration [9]. Although 
calcium channel antagonists are considered to be 
rather weak inhibitors of calcium uptake by brain 
synaptosomes [21, 29], some recent evidence suggest 
that in certain cell lines such as cerebellar granule 
cells, there may be powerful inhibitors of calcium 
uptake [15]. It appears that a reduction of in­
traneuronal free calcium concentration induced via 
different mechanisms might be an important factor 
contributing to the induction of yawning. Among the 
various intraneuronal processes mediated by calcium 
a particular attention has been paid to the regu­
lation of adenylate cyclase activity [8] . Activation 
of adenylate cyclase activity by calcium might lead 
to an accumulation of cyclic adenosine monophos­
phate. In our previous study D1 receptor agonist 
SKF 38 393 which induces an increase of dopamine 
sensitive adenylate cyclase activity [25], had an 
inhibitory effect on the yawning induced by apo-
morphine [31]. In this study milrinone which is 
known to inhibit phosphodiesterase activity and 
thereby induces an increase in cyclic adenosine 
monophosphate level [22] possessed also an in­
hibitory action against nifedipine-induced yawning. 
Muscarinic cholinoreceptor agonists and dopamine D2 
receptor agonists also inhibit adenylate cyclase 
activity [13, 26]. It is not excluded that the cyclic 
adenosine monophosphate level.may be an important 
factor involved in the induction of yawnings. However 
this proposition remains highly speculative and 
needs further investigation. In conclusion the data 
of our experiment, indicate that the calcium channel 
antagonist-induced yawning may represent a con­
venient tool for studying psychotropic activity of 
these drugs. 
7* 
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MECHANISM OF HYPOTENSIVE ACTION OF 
ANGIOTENSIN II AND BRADYKININ 
CYCLOANALOGUES 
V. Golubeva, M. Ratkevica, E. Porunkevich, 
V. Kluša 
Institute of Organic Synthesis, Latvian Academy 
of Sciences, Aizkraukles ZI, Riga 
Abstract 
Modified cyclic analogues of the peptide an­
giotensin II and bradykinin, unlike the natural 
linear precursors characterized by short-term hy­
pertension and short-term hypotension, respect­
ively, exert a long-term dose-dependent hypotensive 
action in nembutal anaesthetized rats upon intra­
venous administration. Our results suggest that 
histamine, serotonin and other endogenous vasoactive 
substances released from mast cells provide the 
hypotensive action of these analogues. 
Introduction 
Total semi-empirical conformational calculations 
carried out for many oligopeptides hawe shown the 
presence of energetically preferable quasi-cyclic 
structures stabilised by electrostatic interactions 
between ionic molecular groups [5] . It has been 
proposed that the synthesis of cyclic analogues with 
limited conformational mobility may open up new 
vistas in designing drugs with enhanced affinity to 
the receptor [5]. 
A pharmacological study of the newly synthesized 
modified cyclopeptides (angiotensin II and brady­
kinin) revealed the appearance of new properties of 
these compounds as compared to their linear pre­
cursors. Thus, the cyclic analogue of angiotensin 
II and the cyclic analogue of bradykinin exert a 
similar long-lasting dose-dependent hypotensive 
action in anaesthetized rats, whereas the natural 
linear kinins - angiotensin II is a typical 
short-term hypertensive agent but bradykinin induces 
a short-term hypotensive effect [1, 8, 9]. Previous 
studies have shown that the influence of angiotensin 
II and bradykinin cycloanalogues on blood pressure 
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is not realized through angiotensin II or bradykinin 
receptors [4, 11]. It is noteworthy that prior 
administration of CaCl2 (100 mg/kg-1) considerably 
reduced the duration of the hypotensive effect caused 
by the cyclic peptides [2, 4]. Nevertheless, the 
mechanism of hypotensive action on these cyclo-
peptides remains obscure. 
The recent studies of cyclic analogues of 
bradykinin and kallidin demonstrating involvement 
of histamine in several vascular permeability models 
of inflammatory responses [17] lead infer that the 
long-lasting hypotensive effect of these cyclo-
analogues may be realized via the liberation of 
endogenous vasoactive substances from depot cells. 
This type of mechanism has been established at least 
for the hypotensive action of vasoactive peptide 
neurotensin [15]. 
Evidence gained in various laboratories indicates 
that histamine and serotonin appear to be involved 
in other biological manifestations of neurotensin 
in rat, e.g. myotropic effect, vasodilatation and 
increase in vascular permeability [7, 12, 15]. 
The present study was conducted to determine the 
role of histamine and serotonin in the hypotensive 
effect of angiotensin II (cyclo-AT) and bradykinin 
(cyclo-BK) eyeloanalogues: 
Asp-Arg-Val-Tyr-Val-His-Pro-Phe angiotensin II 
Lys-Ala-Val-Tyr-Ile-His-Pro-Phe-Arg cyclo-AT 
Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg bradykinin 
Lys-Pro-Pro-Gly-Phe-Gly-Pro-Phe-Arg cyclo-BK 
Methods 
The effect of cyclo-AT (2,10 Hg/kg-*) and cyclo-BK 
(10, 50 |ig/kg-l) on mean arterial pressure upon 
intravenous administration was measured in 
randomly-bred rats of both sexes weighing 180-220 
g. Nembutal 40 mg/kg-*) injected intraperitoneally 
was used for anaesthesia. Corotid arterial pressure 
was registrered with the aid of a Bent ley Trantec 
Physiological Pressure Transducer and a Gemini 
2-channel recorder (Italy). Peptides dissolved in 
0,9 % NaCl were injected into the femoral vein (0,1 
ml/200 g of body weight). Intal (disodium cromo-
glycate, 10 mg/kg"*), stabilizer of mast cell 
membranes; diphenhydramine (5 mgVkg) - H^-receptor 
antagoginst; Cimetidine (10 mg/kg~*) - ^ -receptor 
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antagonist and methysergide (200 Mg/kg"*) - sero­
tonin receptor antagonist were injected intra­
venously 5-10 min. prior to cyclopeptide adminis­
tration. Parachlorophenylalanine, a serotonin 
synthesis inhibitor (400 mg/kg-*), used as a sus­
pension with TWEEN-80, was injected intraperito-
neally 24 hours prior to cyclo-BK administration. 
The histamine liberation assay was performed as 
described [10], using peritoneal mast cells from 
female rats (200-300 g). Histamine content was 
assayed fluorometrically [13]. Intal was added in 
the incubation media simultaneously with cyclo-BK. 
The following drugs were used: serotonin-crea-
tinin sulfat (Reneal), histamine diphosphate 
(Fluka), methysergide maleate (Sandoz), diphenhy­
dramine (Sigma), Cimetidine (Sigma), Intal (dina-
trium cromoglycate)(Leek). 
The measured values are means ± SEM. Comparison 
of treatment effects was made by Student's test; p 
< 0.05. 
Results and Discussion 
According to our hypothesis postulating that 
histamine and serotonin belong to factors respon­
sible for the hypotensive action of cyclic kinins, 
we blocked the histamine component of arterial 
pressure regulation by pretreament with the H^-, 
H2~antagonists diphenhydramine and Cimetidine, 
respectivly. The serotonin component was examined 
using the classical antagonist methysergide and the 
serotonin synthesis inhibitor parachlorophenyla­
lanine . 
As can be seen from Table I, the H^-antagonist 
diphenhydramine (5 mg/kg~l) diminished the hypo­
tensive effect of cyclo-BK (10 |ig/kg-1) by 32 %, 
thus indicating with reasonable plausibility the 
histaminergic portion of the hypotensive action. 
The H2~antagonist Cimetidine failed to influence 
the cyclo-BK action. Cimetidine also failed to alter 
the effect of diphenhydramine (Table 1). Similar 
characteristics are also typical for exogenous 
histamine (Table 1) and the results obtained are in 
good agreement with the literature data suggesting 
the prevailing participation of H^-receptors in 
histamine-induced hypotensive avtion [16]. Attempts 
to block the hypotensive effect of cyclo-BK by using 
the classical serotonin antagonist methysergide were 
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Table 1 
Comparative influence of the test-drugs pretreament on the changes of the 
blood pressure induced by intravenous injection of cyclic bradykinin, his­
tamine and serotonin. 
Drugs Experimental conditions Changes of blood 
pressure (mm Hg) 
Cyclic Control -62,0 ± 4,6 
bradykinin 
(10 ng/kg-1) 
After diphenhydramine 5 mg/kg-* -42,8 ± 6,2* 
After diphenhydramine 25 mg/kg-* -15,2 ± 3,4* 
After Cimetidine 10 mg/kg-* -69,3 ± 8,4 
After Cimetidine 10 mg/kg-* + 
+ diphenhydramine 5 mg/kg-* 
-41,8 ± 5,6* 
After methysergide 200 mg/kg-* 61,1 ± 4,4 
After methysergyde 200 mg/kg-^ + 
+ diphenhydramine 5 mg/kg~l 
-35,8 ± 6,5* 
After parachlorophenylalanine 
400 mg/kg-* 
-36,2 ± 5,6* 
After parachlorophenylalanine + di­
phenhydramine 5 mg/kg~l 
-29,5 ± 5,9* 
Histamine Control -62,3 ± 7,7 
(20 Hg/kg-1) After diphenhydramine 5 mg/kg-* -5,5 ± 3,8* 
After Cimetidine 10 mg/kg-* -64,9 ± 8,7 
Serotonin Control -36,0 * 4,4 
(80 ng/kg-1) After methysergide 200 mg/kg-* -15,9 ± 3,1* 
The results are expressed as M ± SEM (n - 6 - 8), * p < 0.05 vs control 
8* 
unsuccessful. However, one should not attach too 
much significance to the failure of these antagonists 
to suppress the responses to cyclo-BK, since the 
hypotensive effect of serotonin could be completely 
(only by 42 %) abolished by methysergide (Table 1). 
Combined administration of methysergide and di­
phenhydramine did not alter the inhibiting influence 
of diphenhydramine on the hypotensive effect of 
cyclo-BK (Table 1). Parachlorophenylalanine, a 
serotonin synthesis inhibitor, abolished the hy­
potensive action of cyclo-BK by 42 % (Table 1). 
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Fig. 1. Effects of angiotensin II (1), bradykinin 
(2), polymixine В (3), cyclobradykinin (4) and 
cycloangiotensin (5) on the histamine release 
from the rat peritoneal mast cells. 
Unfortunately, no additive action could be noted 
when the two drugs - diphenhydramine and parach­
lorophenylalanine were administered together f^able 
1). These results strongly suggest that his'amine 
Histamine release, % 
vn 
P 
и 
о 
о 
н 
V-N 
н 
60 
and serotonin contribute substantially to the hy­
potensive action of cyclo-BK, and, possibly, 
cyclo-AT in anaesthetized rats. This conclusion is 
based mainly on the fact that the hypotensive effect 
of cyclo-BK becomes significantly reduced in rats 
pretreated with the antihistamine drug diphenhy­
dramine and the serotonin synthesis inhibitor pa-
rachlorophenylalaline. 
Effective liberation of histamine from rat 
peritoneal mast cells by cyclo-BK and cyclo-AT in 
the 10~13 - 10~5 M range of concentration provides 
convincing evidence for histamine involvement in 
manifestation of long-lasting hypotensive effect of 
cyclo-BK and cyclo-AT (fig. 1). Linear angiotensin 
II does not liberate histamine from rat mast cells 
in the 10~6 - 10~4 и concentration range. According 
to their ability to liberate histamine the studied 
cyclopeptides and the well-known histamine liberator 
polymixin В can be ranged in the sequence cyclo-AT 
> cyclo-BK > polymixin В > bradykinin. 
Cross-tachyphylaxis observed with the cyclo­
peptides in vivo is indicative of interaction either 
with the same receptor sites or with different 
receptors but via a common cellular mechanism - in 
our case, the liberation of endogenous substances 
from mast cells. The results of radioligand assay 
have shown that cyclo-BK and polymixin В inhibit 
the binding of labelled cyclo-AT with receptors in 
a competitive manner [6] . 
Recently, it has been claimed that the mast cells 
triggering effect may be dependent on certain 
structural elements: the hydrophobic chain and the 
hydrophilic moiety with positively charged amino 
acids associated with the negatively charged com­
ponent of the membrane surface, thus resulting in 
their decreased mobility which might be initial 
event of mast cells activation similar to the action 
of polycations [5]. It is possible that synthetic 
cyclopeptides containing positively charged amino 
acids (-Lys - Arg -) realize their action via the 
negatively charged component of the mast cell 
membranes. A similar mechanism might also explain 
the abolishment of hypotensive effect of cyclo­
peptides by pretreatment with CaCl2, which, being 
positively charged, binds to the negatively charged 
components of the mast cell membranes, stabilizes 
them and makes them resistant to the action of 
cyclopeptides. The involvement of membrane process 
61 
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Fig. 2. The influence of Intal pretreatment on the cyclopeptides-induced changes in 
mean arterial pressure (MAP) of anaesthetized rats (n - 5-7). 
1 - saline + cyclopeptides; 2 - Intal + cyclopeptides; 
arrow indicates saline or Intal administration; * p < 0.05 vs control 
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in the liberation of endogenous substances triggered 
by cyclopeptides is also confirmed by data obtained 
with Intal, a drug used in the treatment of allergic 
bronchial asthma and for mast cell membranes sta­
bilization. As shown in Fig. 2, prior administration 
of Intal completely reduced the short-term hypo­
tensive effect of small doses of cyclo-BK and 
cyclo-AT (Fig. 2A) and shortened the duration of 
the long-term effects of their large doses (Fig. 
2B). Intal abolished the liberation of histamine 
from rat perioteneal mast cells by cycloOBK (10~6 
M) in a dose-response dependent manner (Fig. 3). 
Histamine release, 
чл 
о 
Fig. 3. Effect of Intal on the histamine release 
induced by cyclobradykinin (10~° M) from the rat 
peritoneal mast cells. 
p < 0.05 vs control 
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This inhibition reaches only 50 % at the maximum 
Intal dose. The present findings demonstrate the 
expedience of further research in this class of 
vasoactive cyclopeptides possesing unusual pro-
perities based on their ability to liberate en­
dogenous hypotensive substances responsible for the 
observed long-term decrease in blood pressure. This 
may serve as a guideline in the search for endogenous 
ligands and in the development of hypotensive drugs 
with a new type of action. 
Conclusion 
1. The hypotensive action of angiotensin II and 
bradykinin eye1oanalogues in partially mediated 
by the release of histamine and serotonin from 
rat mast cells. 
2. Angiotensin II and bradykinin eyeloanalogues 
trigger the release of histamine from rat per­
itoneal mast cells. 
3. The hypotensive action of cyclo-AT and cyclo-BK 
in vivo liberation of histamine from peritoneal 
mast cells in vitro are significantly reduced by 
prior administration of Intal, a drug capable of 
stabilizing mast cell membranes. 
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Abstract 
The effect of systemic administration of 
caerulein and pentagastrin on rat brain benzo­
diazepine, opiate, and GABA receptor characteristics 
was examined in radioligand binding analysis. It 
was shown that the CCK-8 agonists can induce certain 
alterations in CNS receptor parameters. Namely, the 
treatment of rats with both caerulein and penta­
gastrin decreases the number of benzodiazepine 
binding sites in frontal cortex and increases it in 
hippocampus. The binding of ^h-GABA in hippocampal 
membranes was also increased. The administration of 
pentagastrin induced some changes also in opiate 
binding, but these phenomena were observable only 
if the higher (sedative) doses of the drug were 
used. The fact that peripherally administered 
neuropeptides may influence the binding char­
acteristics of CNS receptors helps to understand 
the behavioral effects of these compounds which are 
believed to penetrate poorly the blood-brain-
barrier . 
Introduction 
It is well documented that the administration of 
anxiogenic drugs may induce severe emotional, 
hormonal, and vegetative reactions both in man and 
in experimental animals [5, 18, 19] . Earlier we have 
observed in behavioral tests that drugs acting at 
cholecystokinin octapeptide (CCK-8) receptors have 
certain effects on the anxiety rate of mice and 
rats. Caerulein and pentagastrin, the CCK-8 receptor 
agonists, reduce the exploratory activity of ro­
dents, whereas proglumide, the CCK-8 antagonist, 
inhibits not only the effect of CCK-8 agonists but 
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also the reduction in exploration caused by an-
xiogenics acting at GABA receptor complex [9] . There 
is some preliminary evidence about possible an-
xiogenic action of CCK-related peptides in man [4] . 
The ability of these peptides to penetrate the 
blood-brain-barrier is expected but not documented 
insofar. However, it seems that several neuropep­
tides exert their behavioral effects through a 
primary target in periphery [14, 17]. Therefore, we 
have examined the effect of systemic administration 
of CCK-8 agonists on the in vitro radioligand binding 
to CNS receptors. The key role of GABA receptor -
chloride channel complex in the neurochemistry of 
stress and anxiety [2, 7, 20] was the reason for 
studying benzodiazepine and GABA low affinity 
binding sites. As the endogenous opiates are sug­
gested to be of importance in some behavioral effects 
of CCK-8 [10] the opiate receptor binding was also 
measured. 
Materials and methods 
Female albino rats of no particular strain 
(Rappolovo Farm, Leningrad) were used in this study. 
The animals were taken from their home cage, injected 
intraperitoneal ly with saline or the drug in a 
randomized order and placed into individual chambers 
separated from each other with plexiglass walls. 
Each control or treatment group consisted of 4 rats. 
The doses of peptides administered were selected 
according to previous behavioral experiments. The 
lowest dose of caerulein or pentagastrin used has 
anxiogenic-like effect on exploratory behavior of 
rats with no evidence for sedative action. The 
highest challenge dose of both peptides has clear 
sedative effect as measured in open field test. 15 
min later animals were killed by decapitation. Brain 
regions were dissected according to Glowinski and 
Iversen [6] . Homogenized brain tissue was washed 
twice in TRIS-HCL buffer (pH 7.4) by centrifugation 
(48 000 g for 20 min) and resuspension. I n  v i t r o  
binding studies to label benzodiazepine binding 
sites were carried out at the presence of 0.2-8 nM 
of ^H-flunitrazepam (spec.act. 85.0 Ci/mmol, Am-
ersham Radiochemicals) in a total incubation volume 
of 500 ц1, containing about 0. 1 mg protein. 10 цто1/1 
of flunitrazepam was used to determine nonspecific 
binding. After 60 min incubation on ice the reaction 
was stopped by rapid filtration over Whatman GF/B 
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filters. The filters were washed with 4 x 3 ml of 
ice-cold buffer and dropped into scintillation 
vials. The ^H-diprenorphine binding assay was 
carried out in polypropylene tubes at the presence 
of 0.125-4 nM of radiolabelled ligand (spec.act. 32 
Ci/mmol, Amersham). The membranes were incubated at 
room temperature for 45 min. Nonspecific binding 
was determined by adding naloxone (10 цто1/1). The 
samples were centrifuged in Beckman Microfuge 12 
for 3 min at 11 000 rpm. The supernataent was 
discarded and the tips of tubes were cut into vials. 
Na+ - independent -^H-GABA binding was measured as 
described by Guarneri et al [8] with some modifi­
cations. The homogenized brain tissue was washed 
twice in TRIS-HCL buffer and frozen overnight. Just 
before binding assay, the membrane preparations were 
thawed and washed in the same buffer for four times 
and then suspended in the buffer at a final con­
centration of 0.4 |-Lg protein for sample. The mem­
branes were incubated at 0 С in a total volume of 
250 p.1 with 100 nM ^ H-GABA (spec, act. 71.5 Ci/mmol, 
Amersham). After 15 min the reaction was terminated 
by rapid centrifugation for 3 min at 11 000 rpm in 
microfuge. The supernatant was discarded, pellets 
washed twice with ice-cold buffer and cut into vials. 
The radioactivity was counted using a Beckman LS -
6800 liquid scintillation counter. The analysis of 
saturation curves was performed using Scatchard 
plots and nonlinear least squares regression 
analysis. Student's t-test for paired observations 
was used to determine statistical significance. 
Protein was measured according to the procedure of 
Lowry et al [13]. 
Results 
As shown in Table 1, systemic administration of 
caerulein resulted in a decrease in the apparent 
number of cortical benzodiazepine binding sites. 
Similar effect was observed after the lowest dose 
of pentagastrin. In hippocampus, the lowest doses 
of both peptides induced an increase in the number 
of benzodiazepine binding sites. In certain doses 
(see Table 1), caerulein and pentagastrin increased 
the affinity of benzodiazepine binding sites for 
radioligand in mesolimbic area. The ^ H-flunitrazepam 
binding in corpus striatum was not influenced. 
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Table 1 
Scatchard analysis of saturation data of ^н-flu-
nitrazepam binding in rat brain membranes after 
acute treatment with CCK-8 agonists. Results are 
from pooled tissue of 4 animals per group. 
Treatment Dose 
(|og/kg) 
®max 
(fmol/mg 
prot.) 
KD 
(nmol/1) 
1 2 3 4 
FRONTAL CORTEX 
Saline 1604 ± 110 1.59 ± 0.39 
Caerulein 0. 1 1311 ± 53 1. 13 ± 0. 12 
Caerulein 1 1068 ± 66* 0.91 ± 0.11 
Caerulein 10 1106 ± 86* 1. 18 ± 0.22 
Saline 1185 ± 93 1.19 ± 0.31 
Pentagastrin 0.5 909 ± 76* 0.79 ± 0.22 
Pentagastrin 5 1204 ± 14 0. 73 ± 0.03 
Pentagastrin 50 1300 ± 75 1.20 ± 0.17 
HIPPOCAMPUS 
Saline 1011 ± 53 0.98 ± 0,15 
Caerulein 0. 1 1172 ± 31* 1. 19 ± 0.06 
Caerulein 1 966 ± 69 1.28 ± 0.25 
Caerulein 10 1038 ± 72 0. 92 ± 0. 14 
Saline 777 ± 56 0. 77 ± 0.16 
Pentagastrin 0.5 992 ± 48* 0. 79 ± 0.13 
Pentagastrin 5 1122 ± 21* 1. 14 ± 0.05 
Pentagastrin 50 875 ± 12 0.87 ± 0.03 
MESOLIMBIC AREA 
Saline 897 ± 45 1. 24 ± 0.10 
Caerulein 0. 1 992 ± 60 0.96 ± 0.10 
Caerulein 1 1011 ± 53 0.85±0.08* 
Caerulein 10 915 ± 91 0.87 ± 0.16 
Continued 
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T a b l e  1  c o n t i n u e d  
1 2 3 4 
Saline 1127 ± 111 1.10 ± 0.20 
Pentagastrin 0. 5 935 ± 27 0.72 ± 0.07 
Pentagastrin 5 866 ± 126 0.50±0. 10* 
Pentagastrin 50 986 ± 97 0.74 ± 0.25 
CORPUS STRIATUM 
Saline 665 ± 74 0.77 ± 0. 18 
Caerulein 0. 1 879 ± 54 0.96 ± 0.11 
Caerulein 1 711 ± 46 1.06 ± 0.12 
Caerulein 10 677 ± 41 0.70 ± 0.09 
Saline 646 ± 155 0.80 ± 0.37 
Pentagastrin 0.5 840 ± 148 0.87 ± 0.29 
Pentagastrin 5 699 ± 57 0.81 ± 0.26 
Pentagastrin 50 652 ± 46 0.70 ± 0.21 
* - P < 0.05 as compared to saline group. 
Scatchard analysis of Зц-diprenorphine binding 
revealed that pentagastrin treatment of rats in­
creased the number of binding sites in frontal cortex 
and decreased it in hippocampus and mesolimbic area 
(Table 2). However, these effects were observable 
after higher doses of the CCK-8 agonist. 
The binding of ^h-gaBA was also influenced by 
the administration of caerulein and pentagastrin to 
rats. Both CCK-8 agonists failed to modify ^H-GABA 
binding in the membranes of frontal cortex but 
increased it in hippocampus (Fig. 1). 
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Table 2 
Scatchard analysis of saturation data of 
3H-diprenorphine binding in rat brain membranes 
after acute treatment with pentagastrin. Results 
are from pooled tissue of 4 animals per group 
Brain region Dose 
(Hg/kg) 
Bmax 
(fmol/mg 
prot.) 
Kq (nmol/1) 
Frontal 
cortex 
0 226 ± 25 1.69 ± 0.29 
0.5 227 ± 40 1.80 ± 0.52 
5 313 ± 18* 2. 03 ± 0.18 
50 318 ± 37 1.99 ± 0.36 
Hippocampus 0 240 ± 25 3.07 ± 0.46 
0.5 221 ± 7 2.39 ± 0.12 
5 133 ± 31 1.19 ± 0.50 
50 114 ± 11* 0. 79 ± 0.15* 
Mesolimbic 
area 
0 262 ± 43 1.64 ± 0.40 
0. 5 204 ± 12 1.33 ± 0.14 
5 239 ± 11 1.49 ± 0.11 
50 108 ± 15* 1.46 ± 0.35 
Corpus 
striatum 
0 365 ± 43 2.03 ± 0.38 
0.5 250 ± 9 1.55 * 0.10 
5 450 ± 19 2.00 ± 0. 12 
50 355 ± 49 2.00 ± 0.38 
* - P < 0.05 as compared to control group 
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Figure 1 
The effect of administration of CCK-8 agonists on 
^H-GABA (100 nmol/1) binding in rat brain mem­
branes. Results are from pooled tissue of animals 
per group and are expressed as per cents from 
control ± SEM. 100 X corresponds to about 800 
fmol/mg protein or about 500 fmol/mg protein in 
frontal cortex and hippocampus respectively. 
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Discussion 
The fact that any exposure to stressful situations 
induces certain alterations in benzodiazepine re­
ceptor binding characteristics is not a new one. 
However, there is no general agreement in the di­
rection of changes of these characteristics. 
Stressful manipulations are reported to increase 
[16, 22] and to decrease [11, 12, 15] the number of 
brain benzodiazepine binding sites. Unfortunately 
there is little evidence about the emotional state 
of "stressed" animals in these studies. In a recent 
study of Bodnoff et al [3] a reduction in novel­
ty-induced fear was paralleled by an increase in 
the number of benzodiazepine binding sites in rat 
brain membranes. However, no attempt was made in 
this study to clarify the brain regions where such 
alterations are present. Our results from this study 
clearly indicate that the administration of an-
xiogenic drugs may induce changes of distinct di­
rection in different brain regions. 
Several authors have suggested that stressful 
manipulations may increase opiate receptor binding 
[1, 21] . In our experiments an increase in the number 
of opiate binding sites after pentagastrin treatment 
was observed in frontal cortex, but in hippocampal 
and mesolimbic membranes this measure was decreased. 
The combination of labelled and unlabelled ligand 
used by us makes it possible to determine only the 
total opiate binding. Therefore the effects of 
anxiogenic drug treatment on separate subtypes of 
opiate receptor remain to be elucidated. However, 
it should be kept in mind that the changes in 
Зн-diprenorphine binding occurred only in case the 
CCK-8 agonist was administered in sedative doses. 
The administration of both caerulein and pen­
tagastrin had no effect on low affinity 3H-GABA 
binding in frontal cortex but increased it in the 
hippocampus of rats. These results seem to be in 
conflict with the experiments of Biggio [2] who has 
found that stress induces downregulation of low 
affinity 3H-GABA binding in rat cerebral cortex. 
However, his group has used a quite different ex­
perimental paradigm involving chronic exposure of 
control animals to stressful situations. 
In conclusion, the results of present study show 
that previous systemic administration of anxiogenic 
(and sedative) doses of CCK-8 agonists may influence 
the CNS receptor binding parameters in certain brain 
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regions. This fact should be considered in dis­
cussions about central versus peripheral origin of 
the behavioral effects of systemically administered 
neuropeptides. 
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NMDA-RECEPTOR: THE BASIC RESULTS OF STUDY 
AND PERSPECTIVES OF CLINICAL 
USE OF ANTAGONISTS 
S.A. Gutnikov 
Laboratory of Psychopharmacology Bekhterev, Psy­
choneurological Research Institute, Leningrad 
Abstract 
Amino acids mediate about a half of the synaptic 
transmission in the mammalian brain. NMDA-receptor 
is the most examined type of excitatory amino acids 
receptors. Structure of NMDA receptor-channel 
complex, agonists and antagonists, their effects in 
animals are reviewed. Use of NMDA-antagonists for 
treatment of epilepsy, hypoxia (including perin­
atal), stroke and neurodegenerative disorders is 
predicted. Involvement of NMDA-receptors in mech­
anisms of psychoses and drug addiction is suggested. 
Bibliography 44 ref. 
Introduction 
History of the study of the excitatory amino 
acids (EAA) has begun in the early 1950s when the 
convulsive action of glutamate and aspartate was 
shown [42]. In the past three decades significant 
advances have been made in understanding the function 
of EAA. The current state of the problem was presented 
at the International symposium "Excitatory Amino 
Acids ' 88" (Brazil, Manaus, March 28 - April 2, 
1988). Its materials are taken as a basis for this 
review. Abstracts from the symposium are published 
in a special issue of Neurochemistry International 
(1988, v. 12, suppi. I.) 
The demonstration of the direct depolarizing 
action of 1-glutamate on spinal neurones in 1958 
led to the speculation that one or more endogenous 
amino acids may act as exctitatory transmitter 
substances in the mammalian central nervous system 
[42] . It is known now that amino acid mediated 
neuronal communication represents at least 50 % of 
the synaptic activity of mammalian brain and 
practically every neuron receives information coded 
through the release of an EAA transmitter [8]. EAA 
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are now considered to play key roles as neuro­
transmitters in epilepsy, spasticity, neurodegen­
erative disorders, anxiety, learning and, probably, 
psychoses. 
The name of amino acids "excitatory" is relevant 
both to cellular and behavioral levels. The effect 
of EAA is considered to be linked with opening of 
the cationic channels in neuronal membrane. Side by 
side with ionotropic mechanism there is a metabo-
lotropic one including the activation of specific 
enzymes [8]. L-glutamate is the common 1igand for 
EAA receptors. According to their specific ligands, 
glutamate receptors are divided into three types: 
N-methyl-d-aspartate (NMDA), kainate and quisqua­
late [36] . It is suggested that metabolotropic effect 
is mediated via a specific fourth type of glutamate 
receptor related to inositol phosphatase [39] . 
EAA receptors are distributed throughout the 
brain [44]. At many central synapses the postsynaptic 
membrane contains a mixture of NMDA and non-NMDA 
receptors [9]
ь 
The distribution and properties of 
these receptors are dynamic, with changes in receptor 
population during normal aging and in response to 
pathological processes such as epilepsy, trauma, 
Alzheimer's disease [9] and hypoglycemic states 
[43]. 
Because of a restricted space of the publication 
I have to dwell on the NMDA-reсерtors only. On the 
one hand this type of EAA receptors is best studied, 
on the other hand namely NMDA-receptor is in the 
focus of our interests because it is the site of 
action of kynurenines - endogenous metabolites of 
tryptophan - whose neuroactivity has been discovered 
and is now intensively studied in our laboratory 
[18-21 ] .  
Molecular organization and structure of NMDA re­
ceptor complex 
NMDA receptor and related ionic channel are 
included in the complex which appears to be of 
protein nature and consists of multiple subunits 
(Fig. 1) [11, 32]. NMDA receptor-coupled ionic 
channel is permeable for cations Na+, К* and Ca++, 
meanwhile ionic channels related to other EAA re­
ceptors are permeable for Na+ and K+ only [7]. At 
least five distinct sites of binding within 
NMDA-receptor complex are: 
1) for agonists and competitive antagonists 
2) for allosteric modulators 
3) for non-competitive antagonists, three dif­
ferent sites for a) Mg++, b) Zn++, c) PCP-like drugs, 
ALLOSTERtC SITE ION CHANNEL 
RECOGNITION 
iITt 
EXmcEUULAR 
INTUCEUVLkfc 
,  RESTING x  (CHANNEL CLOSED) 
GLYCINE, 
«SERINE 
GLUTAMATE. 
NMDA, 
QUIUOLINIC 
AN,APS, 
AP?, CPP, ^  
C6S 19155 
KYNURENIC 
ACID 
PCP, л 
MK-601. 
KETAMINE, 
6-OPIOIDS 
ff  
•;y 
» • • • • 
L'-v-f.: 
К
4 *  A C T I V A T E D  (CHANNEL OPEN) 
Fig. 1. NMDA receptor-channel complex (according to 
A.C. Foster and G.E. Fagg (1987), modified). 
For legends see the text. 
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NMDA-receptor agonists. NMDA-receptor received 
its name from N-methyl-D-aspartate (NMDA) - a first 
specific synthetic agonist [36]. Non-specific en­
dogenous agonists are 1-glutamate and 1-aspartate. 
Cyclic analog of NMDA, quinolinic acid, which is 
the normal constituent in a mammalian brain [31] is 
considered to be an endogenous specific agonist 
[37]. 
Competitive antagonists bind to the agonist 
recognition binding site but do not open the ionic 
channel. This group includes phosphonic derivatives 
of amino acids: 2-amino-4-phosphonobutyrate (APB, 
AP4), 2-amino-5-phosphonovalerate (APV, AP5), 
2-amino-7-phosphonoheptanoate (APH, AP7), 3-(2-car-
boxypiperazin-4-yl)propyl-I-phosphonic acid (CPP) 
[11, 36, 37] and cis-4-phosphonomethyl-2-piperidine 
carboxylic acid (CGS 19 755). 
Allosteric modulators. NMDA receptor exists in 
agonist and antagonist preferring conformations. 
Glycine and D-serine allosterically convert anta­
gonist-preferring conformation into agonist-pref­
erring one and reduce antagonist binding while 
enhancing agonist binding [15, 29]. Kynurenic acid 
has an opposite effect [15, 24, 28]. It is worth 
noting that two functional antagonists, i.e. qui­
nolinic acid and kynurenic acid, are metabolically 
closely interrelated because both are endogenous 
metabolites of tryptophan at the kynurenine pathway 
[4, 19. 31, 35, 38]. 
Noncompetitive antagonists. Binding sites for 
noncompetitive antagonists are located inside the 
open state of NMDA receptor-copuled ionic channel. 
They act by direct channel blockade ("like a cork"). 
Mg+ + cation blocks the channel in a voltage-dependent 
manner [1]. Its binding site is located apparently 
near to the internal surface of the membrane. Another 
cation - Zn++ - has its own binding site. There is 
evidence that tricyclic antidepressants (organic 
molecules!), most effectively desmethylimipramine, 
bind to the Zn++-recognition site [34]. 
PCP-like drugs recognition site is the third 
binding site inside the channel. This group includes 
phencyc1idine (PCP; l-(l-phenylcyclohexyl)-piperi-
dine), ketamine (±))-2-o-chlorophenyl-2-methylami-
nocyclohexanone), MK-801 (( + )-5-methy1-10,11-dihy-
dro-5-dibenzo(a,d)eye1ohepten-5,10-iminomaleate) 
and sigma-opioids: cyclazocine, pentazocine and 
N-allyl-normetazocine (NANM, SKF 10,047). According 
to their activity they are rated in an such order: 
MK-801 > PCP > cyclazocine > ketamine > SKF 10,047 
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> pentazocine [24]. The presence of an endogenous 
ligand for PCP-binding site - so called alfa-en-
dopsychosine - is also suggested [8]. 
Thus, the NMDA receptor system is a remarkable 
complex entity, the normal function of which depends 
on a dynamic equilibrium among multiple facilitative 
and inhibitory factors. 
Effecte of NMDA agonists and antagonists 
NMDA-agonists induce membrane depolarization and 
excitation of neurons. This is manifested 
dose-dependently in locomotor hyperactivity [33] 
and seizures on electrophysiological [17] and be­
havioral [18, 20, 33] levels. Excessive excitation 
is followed by neurodegeneration through rapid Ca++-
independent or slow Ca++-dependent mechanisms [7]. 
NMDA agonist-induced neurodegeneration is char­
acterized by destruction of only neuronal bodies 
associated with the safety of sparing axons and 
glial proliferation [3]. 
Data about synergism between glycine and 
NMDA-agonists are true for in vitro experiments. In 
vivo administration of glycine in rats antagonized 
excitatory and convulsive effects of quinolinic 
acid, NMDA receptor agonist [20]. 
NMDA-antagonists effects are presented in the 
literature more widely. Besides the effects opposite 
to the mentioned effects of agonists, i.e. anti­
convulsant [6, 16, 20, 28, 37] and neuroprotective 
in agonist-induced neurodegeneration [26, 37] 
NMDA-antagonists possess the following effects: 
- anxiolytic (for competitive antagonists only) 
[23], 
- impairment of certain kinds of learning and 
memory [10, 30], 
- muscle relaxation (in genetically spastic 
rats) [40], 
- catalepsy (in pigeons), locomotor activation, 
stereotyped sniffing, head movements, loss of 
motor coordination, ataxia (in rodents), 
anesthesia, nystagmus and profuse salivation (in 
rhesus monkeys) [16], 
- neuroprotection in hypoxia [12], including 
hypobaric [14], and in hypoglycemia [41], 
- preventig of edema and restoring of magnesium 
homeostasis after traumatic brain injury [27]. 
82 
Known competitive NMDA-antagonists do not penetrate 
through the blood brain barrier and are effective 
only under intracerebroventricular (i.e.v.) ad­
ministration. Noncompetitive antagonists including 
the most active one - MK-801 - may be administred 
systemically. There is the following order of 
NMDA-antagonists potency according to their beha­
vioral effects: CPP (i.e.v.) > MK-801 (i.e.v.) > 
PCP (i.c.v.) > MK-801 (i.p.) > AP5 (i.e.v.) > 
kynurenic acid (i.c.v.) > PCP (i.p.) > CPP (i.p.) 
> ketamine (i.p.) [16]. 
To the effects observed in the experiments on 
laboratory animals we can add some clinical effects 
of PCP and ketamine which have begun to be used in 
humans long time before the discovery of their 
relation to the NMDA-receptors. These drugs belong 
to the group of the so-called "dissociative anes­
thetics". They induce analgesia and short-time 
general anesthesia. On the other hand, after 
emergence they induce hallucinations, changes in 
perceived body image, feeling of detachment from 
the enviroment, deficits in cognitive ability, 
sometimes aggressive behavior [2, 13]. In case of 
PCP these side effects are so severe that a PCP-model 
of schizophrenia has been suggested [5]. 
Although tricyclic antidepressants are also used 
in humans, their effects cannot be considered as 
the effects of the NMDA-receptor blocade because 
their NMDA-inhibitory potency is relatively weak in 
comparison with their well-established effects on 
the monoamine uptake system [34]. 
Clinical use of NMDA-antagonists: perspectives 
There is evidence that the anticonvulsant and 
neuroprotective action of NMDA-antagonists can be 
used in the case of epilepsy and some neurodegen­
erative disorders such as Alzheimer's disease, 
Huntington's chorea, lateral amiotrophic sclerosis 
because of a great similarity between morphological 
changes in these disorders and the NMDA ago-
nist-induced (e.g. quinolinic acid-induced) neu-
rodestruction. 
So far as NMDA-antagonists are potent against 
neurodegeneration in perinatal hypoxia, ketamine, 
a clinically used anesthetic has certain advantages 
over other analgesic drugs for use during the de­
livery. Its neuroprotective action would be of great 
use against hypoxia. On the other hand, because of 
psychotic side effects of ketamine the after-effects 
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of even single ketamine administration on the fetus 
must be thoroughly examined. It cannot be excluded 
also that insignificant addictive properties of 
ketamine in adults (occasional observations) may be 
dangerous in the earliest age. 
PCP, a more active analog of ketamine, was not 
introduced in wide clinical practice due to its more 
severe psychotic side effects and significant ad­
dictive potency. Thus, the effects of PCP-like drugs 
may be tentatively classified into two, groups: 
1) "positive" - analgesic (clinical data), 
anticonvulsant and neuroprotective (experimental 
data), 
2) "negative" - psychotomimetic and addictive 
(clinical data). 
While the experimental "positive" effects are 
proved to be related to the blockade of NMDA 
receptor-coupled cationic channel, the involvement 
of EAA system in "negative" ones and analgesia is 
still unknown. The following questions have to be 
answered: 
1) Does the EAA system participate in mechanisms 
of analgesia, psychoses and drug addiction? 
2) If yes, what is the ratio of NMDA-antagonist 
and sigma-opioid agonist properties in these effects 
of PCP-like drugs? 
Answers to these questions may lead to new ap­
proaches in treatment of psychotic states and drug 
addiction. 
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Abstract 
This mini-review has been dedicated to some 
regulation aspects of the oligomeric systems 
(transport and receptor proteins). It has been shown, 
that the brain Na, K-ATPase cooperativity for Na+ 
and K+ depends on enzyme's oligomeric state and that 
lipid-protein interactions participate in main­
taining enzyme oligomerization levels. Experimental 
data suggest that one of biochemical mechanisms in 
genesis of some pathological processes with in­
creased intracellular Na + (tumorous diseases and 
hypertension) involves (through several ways) 
disturbances at the higher oligomerization levels 
(allosteric properties) of Na, K-ATPase, that leads 
to a decrease in positive cooperative binding of 
Na+. Disturbanses of oligomerization level of the 
transport and receptor proteins are really asso­
ciated with genesis of pathological states. 
In the past decade there has been collected a 
valuable information about Na, K-ATPase subunits (a 
and ß) and their primary structure [1, 4], never­
theless there is little known as yet about the 
mechanisms by which the regulation of the Na-pump 
would take place. We can claim without doubt that 
decoding of this enzyme-system regulation mechanism 
is, however, a very important problem, which con­
siderably develops our conceptions about oligomeric 
systems in general. 
In the present mini-review we make an attempt to 
analyze some aspects of regulation of the brain Na, 
K-ATPase with main attention concentrated to the 
following questions: 1) Does the cooperativity for 
Na+ and K+ depend on the degree of enzyme proto-
merization (oligomerization)? 2) Which role do the 
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lipids play on the occasion of activating (or co­
operative) effects of essential cations? 3) Do any 
regulatory properties of the Na, K-ATPase alter 
genesis in some pathological states? 
Brain Na-pump is integrated in the plasmatic 
membrane protein, the protomer (aß) of which consists 
a - and ß-subunits [8]. Na, K-ATPase is characterized 
by cooperative interactions with Na+ and K+ [2, 13], 
at the same time the membrane lipids have been 
evidently engaged in regulation of the functioning 
of the Na, K-ATPase [8] . It has also been shown, 
that under several pathological states Na, K-ATPase 
activity undergoes certain alterations [5] . 
It is very logical that the regulation of this 
oligomeric enzyme system (Na-pump) realizes through 
the interactions at several structural levels of 
enzyme protein (subunit, protomer etc.). Therefore, 
it is clear that a more constructive approach to 
the regulation of the intact Na, K-ATPase system 
needs generalized information, obtained from the 
experiments wrth normal and desensitized enzyme 
preparations (EP) and with EP, treated with phos-
pholipase or modifiers (including pharmacological 
agents) or isolated from the pathological brain 
tissue. By desensitization of the enzyme oligomeric 
structure with several factors (urea, DS-Na, 
digitonin, CHAPS) under a variety of conditions 
without and with substrates (ATP, pNPP) and after 
following determination of different kinetic 
characteristics (17, 14) it should be suggested that 
in the usual activation process of Na, ATPase by 
Na+ and K+ the noninteracting (noncooperative) 
cation-binding sites play a desicive role, while 
their affinity to Na+ and K+ differs from the affinity 
of the cooperative cation-binding sites. Another 
assumption is also possible - the same cation-binding 
sites participate in the both processes (activation 
and cooperativity), but the cooperativity of these 
sites appears definitely, only in the case of in­
teractions of the components of the enzyme system. 
This possibility is supported by the observation 
that at the level of noninteracting (individual) 
subunits the binding of Na+ and K+ to Na, K-ATPase 
was noncooperative, while enzyme activity was not 
practically altered [14]. Accordingly, in order to 
reveal the cooperativity of Na+ and K+ at all, it 
is necessary (as a minimum), to reach the protomeric 
level of the enzyme. In other words, the quintessence 
12* 
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of the cooperativity lies in protein-protein (in-
terprotein) interactions. However, for the mani­
festation of complete cooperativity towards Na+ and 
K+ the existence of cessary protomer-protomer 
(interprotomer) interactions [14] necessary. At the 
same time, it should be specially emphasized that 
a complete cooperativity for Na + , unlike that for 
K+, can be maintained only under conditions of 
nondestroyed interprotomer interactions. Conse­
quently, the cooperativity for Na+ (or enzyme al-
losteric properties for Na+) disapears more easily 
than the cooperativity for K+. These suggestions 
were supported by desensitization experiments [14] 
and by the facts, that in EP from a tumorous brain 
tissue (TBT) the positive cooperative binding of 
Na+ to the enzyme was absent while the binding of 
K+ was quite normal [3]. Besides, by inhibition of 
enzyme activity with Mg2+ [11], alongside the de­
crease in intersubunit interactions, there is always 
a remarkeble change in the Na, K-ATPase affinity 
and cooperativity for Na+. In the case of K+ this 
feature is less pronounced. 
The above-mentioned assumptions have been sup­
ported by the experiments with psychotropic drugs 
(PD). For example, it has been established that PD 
compete with cations for the regulatory ca­
tion-binding sites of oligomeric complex [16]. 
Another finding is that in the presence of both Na+ 
and K+m when the enzyme works at Na, K-regime, most 
of PD (being found to exert positive cooperative 
effect) compete with Na+. AT the same time only 
single PD showed competition (rise the KQ 5) with 
K+ [13]. The desensitization experiments are also 
a good evidence for the presumption that PD coop­
erative binding with Na+- and K+-sites requires 
certain oligomerization levels of the enzyme pro­
tein. Thus, DS-Na treatment of EP diminished the 
Hill coefficients for the antidepressant imipramine 
and psychostimulator ritaline to the unit [13, 16]. 
Generalization of the above-mentioned data allows 
to answer the first question in the following way: 
Na, K-ATPase cooperativity for Na+ and K+ depends 
in fact on the levels of enzyme protomerization 
(oligomerization). 
Among the physico-chemical interactions (for 
example, interprotein interactions), which guar­
antee a synchronous functioning of the Na, K-ATPase 
during the Na+ and K+ transmembrane transport, 
attention has recently been called to membrane lipids 
because of their regulator role for the activity 
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and functioning of the Na, K-ATPase (see for example, 
9). According to the current conceptions [9], lipids 
controlling role in the regulation of the Na, K-
ATPase realizes through two interdependent ways: by 
changes in membrane microviscosity (a feature of 
phasic transitions) and hydrophobic volume of 
plasmatic membrane. Let us analyze the brain Na-pump 
experimental material on the basis of these con­
ceptions. Nowadays it is considered that the typical 
break on the Arrhenius plot (at 19-22 °C), obtained 
by membrane EP, reflects phasic transitions in the 
lipid bilayer [8]. This break has been obtained also 
on the occasion of the brain Na, K-ATPase, whereas 
after the treatment with phospholipase A2 this break 
disappears, i.e. the curve becomes linear [15]. At 
the same time there there has been found an in­
teresting feature: after treatment of EP with the 
desensitazers (urea, digitonin), which causes the 
most significant alterations in the amounts of 
sulfhydryl groups [14], the break on Arrhenius plot 
at 27.5 - 30.5 °C was detected [6]. 
The above-mentioned features could be explained 
with the help of two suggestions: first, the tem­
perature interval of 27.5 - 30.5 С is evidently 
linked to certain alterations linked to certain 
alterations (apparently local) in the enzyme protein 
conformation leading to some changes in the SH-groups 
packing. This viewpoint is supported by different 
protective effects of the ATP against the modificator 
(pCMB) of SH-groups at 37 °C and 28.5 - 29.5 °C and 
in the fact that after treatment of EP with urea 
and digitonin the break manifests itself at 28.5 -
29.5 °C with and without ATP [15]. In favour of the 
latter fact is the evidence that high concentrations 
of ATP can release the enzyme but of the control by 
membrane lipid moiety [9] . The fact that urea and 
digitonin (but not Ds-Na and CHAPS) did not re­
markably affect the phospholipid content of membrane 
fragments speaks also in support of this presumption 
(our unpublished data). 
Secondly: it may well be that the break on 
Arrhenius plot at 2 7.5 - 30.5 °C is linked to a 
membrane lipid state, while this break was par­
ticularly pronounced on the occasion of EP from TBT 
[6] . It must be added that membrane lipids in normal 
brain tissue (NBT) EP differ from those in TBI (see 
below). In connection with the latter it is in­
teresting to mention the fact that in case of TBI 
no cooperative Na+ binding to NA, K-ATPase has been 
established [3] . 
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Membrane lipids effects on the enzyme protein 
moiety conformation are realized also through the 
alterations in the membrane hydrophobic volume. 
Proceeding from this viewpoint, it is interesting 
to know how the hydrophobic biological modulators 
would effect the brain Na, K-ATPase. 
It was demonstrated that prostaglandin E2 (PGE2) 
inhibits allosterically both the whole Na, K-ATPase 
reaction (njj - 1.4) and the partial K-phosphatase 
reaction (пц = 1.3) [16]. Since the PGE2 is sig­
nificantly hydrophobic and the break on the Arrhenius 
plot (at the same time the activation energy in the 
low-temperature region increases), we can suppose 
that PGE2's cooperative effects on the Na, K-ATPase 
include both an immediate effect on the 
phase-structural transitions of membrane lipids and 
changes in membranes hydrophobity. Obviously, the 
PGE2~induced alterations of Na, K-ATPase lipid 
surroundings are transferred via the reciprocal 
lipid-protein contacts to the oligomeric protein. 
Through this mechanism the allosteric regulation by 
the abovmentioned biological modulator is realized.' 
Summarizing the facts and assumptions presented 
above we can give the following answer to the second 
question. Lipid-protein interaction play certain 
role in regulation of the Na-pump of the brain, 
whereas without doubt the lipid-protein contacts 
take part through the interdependent ways (expe­
riments with prostaglandin are a good evidence for 
this interconnection) in the guarantee of the 
cooperativity for Na + and K+ with oligomeric enzyme. 
However, it would be emphasized that in case of more 
deep disturbances of lipid-protein interactions (for 
example, in case of various pathologies) besides 
changes in microviscosity and hydrophobity also the 
products of lipid metabolism, especially, the 
products of lipid peroxidation (LP) can play a 
decisive role in regulation of Na, K-ATPase. 
The literature cites numerous facts that in 
various pathological states Na, K-ATPase activity 
is altered. However, there is not much known yet 
about concrete alterations of the Na-pump in these 
conditions. In the present paper we analyze the Na, 
K-ATPase from TBT on the ground of this aspect. 
Thus, it appears that the common biochemical 
parameters (optimal concentrations of Na+, K+, Mg2, 
ATP and pH-optimum) for EP from TBI and from NBT 
were nearly identical. At the same time, it was 
established that in case of TBT the break on the 
Arrhenius plot is not located at 20-22 C, but is 
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detectable at 27.5 - 30.5 °C [6]. Besides, there 
was no positive cooperative Na+ binding with the 
enzyme from TBT, while the cooperativity for K+ was 
normal [3] . 
It is clear, that the above-mentioned evidence 
produces several considerations. For example, if 
one suggests, thaet a typical break on the Arrhenius 
plot at 19-22 "c reflects the membrane lipids 
microviscosity and the hydrophobic volume changes, 
then the break in the higher temperature region (at 
27.5 - 30.5 °C), would be linked mainly to certain 
local changes in the conformation of Na, K-ATPase 
oligomeric protein and, on the other hand, also to 
some alterations in the composition of proteinic 
components in case of TBT [3]. However, it can not 
be excluded, that in the above-mentioned differences 
of Na, K-ATPase from TBT and NBT, changes at 
lipid-protein interactions level play a certain 
role. In favour of the latter conception is the 
evidence, that there is a considerable distinction 
between the nonsaturability index of phospholipids 
in membrane fragments from TBT and NBT with an 
essential difference in the total content of the 
mentioned phospolipids (our unpublished data). It 
is interesting that the nonsaturability of phos­
pholipids is in good agreement with the higher 
content of LP products in tissue and EP-s from 
tumours brain compared with that of normal brain 
[ 6 ] .  
On the basis of the above-mentioned facts and 
conceptions it should be summarized, that the pa­
thologies with disturbances of interconnections 
(which guarantee the higher oligomerity levels for 
Na, K-ATPase) are followed (or associated) by the 
changes in the enzyme-system allosterical properties 
for essential cations, especially for Na+. As regards 
lipids, then in pathological states, besides other 
effects a considerable role can play their metabolism 
products (including the products of LP) which modify 
the lipid-protein contacts. 
In conclusion, attention should be paid to an 
interesting aspect. The analysis of certain facts 
allows to assume, that there really exists a bio-
logical-logical relation between pathologies and 
alterations of the amount and cooperative properties 
of the Na, K-ATPase. For example, in the case of 
TBT cooperative Na+ binding with Na, K-ATPase 
disappeared. At the same time it is known that the 
tumorous cells show higher Na+ content and increased 
relationship of Na+/K* which is connected with the 
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intensive transcription feature [10]. On the basis 
of the above-mentioned and literature facts we can 
put forward a hypothesis according to which the 
disturbance (disappearance) of the positive coop­
erative nature in Na+ binding with Na, K-ATPase (as 
a guarantee for the effective transport Na+ from 
cell), formed a basis for the Na + accumulation in 
the tumours cell that is connected with their 
intensive growth. Virtually, with this phenomena at 
Na, K-ATPase level, with simultaneos changes in 
enzyme amounts and with the excistence some en­
dogenous inhibitors may, in our opinion, be explained 
the role of Na-pump in certain pathologies, char­
acterized by the increased intracellular Na+ for 
example, in hypertension genesis (see 7). 
No doubt, the regulation of oligomeric transport 
and receptor proteins through their oligomerization 
level is one of the most universal and flexible 
regulatory principles, the disturbance or disap­
pearance of which leads to certain pathological 
states. 
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Abstract 
A direct undamaging micromethod for studying the 
synaptic pharmacology is described. The method is 
based on the registration of the so called quantum 
of EEG, i.e. the mass extracellular monosynaptic 
potential generated by the synapses of a single 
presynaptic fiber. Advantages of the method are 
illustrated .by examples of experiments on the frog 
tectum, d-tubocurarine (0.1 mmol/1) differentially 
inhibits the quanta of EEG, CdCl2 (10 - 200 цто1/1) 
inhibits all the quanta of EEG, and ethanol 
(0.2 - 0.5 mol/1) augments the presynaptic spike. 
When pair facilitation is also studied it is possible 
in some cases to differentiate between pre- and 
postsynaptic receptors. 
Introduction 
The main studies of synaptic pharmacology have 
been carried out with macromethods, e.g. regis­
tration of evoked potentials. Intracellular elec­
trodes damaging the cell are also frequently used. 
Mass extracellular evoked responses and compound 
postsynaptic potentials might mislead us since 
relative refracterity and collective phenomena are 
possible when many nerve fibers are excited. Besides, 
as a rule, inhomogenous population of synapses is 
involved in these events. Synaptic pharmacology 
needs other approaches, stimulation of one nerve 
fiber and undamaging derivation of synaptic po­
tentials are preferable. 
Registration of the quantum of EEG meets these 
requirements. The quantum of EEG is a mass extra­
cellular monosynaptic potential generated by a set 
of synapses of a single fiber when one presynaptic 
spike arrives in its terminal brush [5, 6] . The 
concept "the quantum of EEG" was introduced when 
13* 
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analysing theoretically the genesis of EEG, es­
pecially for understanding the high frequency EEG 
[5]. It has been stated that the quantum of EEG is 
an elementary impulse of mass potentials of the grey 
matter and that this impulse may be derived by the 
spike trigerred average of ECoG. This statement is 
based on the physics of bioelectricity and on the 
analysis of statistical structure of EEG. 
Registration of the quantum of EEG is accomplished 
in various preparations by the neurophysiologists 
of the Kaunas Medical Institute [3, 4, 7, 9] and by 
a number of investigators in the USSR and abroad 
[2, 16, 17, 19]. Thus, there is a real new method 
in the physiology and pharmacology of central 
synapses. The method is equally good for proxymal 
and dendritic distal synapses, in all cases the 
population of synapses is probably homogeneous. When 
the presynaptic fiber or its cell is electrically 
stimulated we can derive the presynaptic spike of 
a single afferent and the extracellular postsynaptic 
potential, i.e. the quantum of EEG, evoked by the 
spike. This makes it possible to study the effects 
of pharmacological substances that have influence 
on the synaptic membrane and on the membrane of 
nerve fibers without complications due to pharma­
cological influence on the membrane potential of 
presynaptic cell, etc. 
Some possibilities to differentiate between pre-
and postsynaptic localization of pharmacological 
effects arise using the method of the quantum of 
EEG when marked frequency facilitation exists. 
Suppose, a blockator equally suppresses all the 
quanta of EEG of a train, it means the postsynaptic 
receptor is blocked independent of its state. 
Contrarily, when the first quanta of EEG are sup­
pressed more in comparison with the later ones, the 
pharmacological effect is presynaptic: frequency 
facilitation counteracts the suppression of ex-
ocytose of the neurotransmitter [11, 13, 15]. There 
may be other possibilities, frequency depression 
may also be useful. 
The choise of a neural object is very important 
for the success of the method. The following re­
quirements should be observed: 1) the presynaptic 
cell or fiber must be accessible for electro­
stimulation; 2) the grey tissue where the quantum 
of EEG is derived should be of a clear and regular 
structure; 3) the presynaptic terminal brush should 
be compact and should have a large number of synapses; 
4) the frequency facilitation should be significant. 
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The classical object of contemporary physiology of 
the CNS, the tectum opticum of the frog, meets all 
these requirements: 1) the presynaptic ganglion 
cells form a monocellular layer on the surface of 
the retina, among the cells there are very large 
ones that can be excited without irritating their 
neighbours; 2) cellular and molecular layers in­
cluding sublayers of tangentially orientated af­
ferent fibers are clearly marked, the apical dendites 
are strictly radial; 3) the terminal brush of optic 
afferente is of ellipsoidic shaps with dimensions 
100 x 30 цт containing about a thousand synapses; 
4) the pair facilitation reaches 2 [8, 10]. 
We suggest the registration of the quantum of 
EEG of the retino-tectal afferent in the frog with 
pair stimulation of the retina as an adequate and 
convenient micromethod for studying the pharmaco­
logical effects on the CNS synapses. 
Methods 
Surgical preparation of the animal. 0.1 - 0.2 mg 
of d-tubocurarino were injected intramuscularly. 
Ten minutes later when the frog was immobilized its 
oral cavity was ventilated with a moistened mixture 
of oxygen (95 7.) and carbon dioxide (5 %). The 
ventilation lasted throughout the experiment. The 
immobilization was supported by an additional in­
jection of 0. 1 mg of d-tubocurarine every 20-30 min. 
0.2 ml of 0.25 % novocaine was injected subcu-
taneously at the point aboive the tectum. 10-15 min 
later the skin was cut off with scissors, and the 
skull was trepanized. The dura mater was excised 
with special scissors, and the pia mater was 
eliminated with a tungsten wire sharpened to 1-2 
цт, the latter operation was visually controled under 
a microscope. The opened surface of dorsal tectum 
was perfused with the Ringer solution (pH 7.2 - 7.3, 
117 NaCl, 2.5 KCl, 1.8 CaCl2, 1.2 NaHC03, 0.17 
NaH2PC>4 • 2H2O - all the values in mmol/1). 0.02 ml 
of 0.25 % novocaine was introduced into each corner, 
besides a piece of cotton-wool moistened with 
novocaine was applied on the eye. Anesthesia com­
pleted, the upper eyelid, the nictating membrane 
and the sclera were excised. The lens,the hyaloid 
were sucked off. The naked retina was periodically 
moistened with the Ringer solution. 
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Electrical stimulation of the retina. According 
to Evert et al. [ 14] and our experience [9] the 
afferente from the nasoventral retina arrive to the 
dorsal tectum which is most convenient for micro-
electrode insertion. A block of 6 stimulating 
electrodes [1] was put on the nasoventral retina as 
much peripherally as possible because in the retinal 
periphery there is minimal density of ganglion cells. 
Every stimulating electrode is a glass-isolated 15 
t-im tungsten wire. One of the 30 variants of bipolar 
stimulation that are possible with the block of 6 
electrodes may be chosen, thus, we can change the 
stimulated area without moving the electrodes along 
the retina. The distance between the centers of 
stimulating poles varied from 60 to 170 pm, the DC 
resistance was equal to 120-700 kO 
The stimuli were one or two pulses of 1 - 5 V, 
20-3 us, the interval between the pulses in a pair 
was 5-50 ms, the frequency of stimulation was 
equal to 0.5 Hz. By changing the pulse duration we 
searched for the threshold of stimulation when the 
evoked response was of "all-or-nothing" type (Fig. 
1). If needed, the location of the registrating 
microelectrode in the tectum was corrected, the 
stimulating bipole was changed, and sometimes even 
the stimulating block was moved along the retina. 
Derivation. We used carbon microelectrodes [12], 
in recent experiments they were modified and a 
diminished electric noise in the low frequency range 
was achieved (the description of electrode 
modification will be published separately). Ac­
cording to the micrometer the microelectrodes were 
inserted into the depth of 0.2 - 0.3 mm where large 
retinal afferente terminate. The "all-or-nothing" 
responses consisted of a presynaptic wave, i.e. a 
spike of the terminal brush, and of a postsynaptic 
wave, i.e. the quantum of EEG, which arrived with 
a delay of 0. 5 - 0.9 ms (Fig. la) . Single or averaged 
responses were registered on the screen of an av­
erager or a computer. The frequency of potential 
reading was 10.6 or 28.4 kHz, the overall frequency 
band was equal to 2 / 5000 Hz. When pair stimulation 
was applied the test quantum of EEG became larger, 
Pair facilitation is A2/A1, where A2 and A^ are the 
amplitude of the test and the conditioned quanta of 
EEG correspondingly. If the interval between the 
pulss in pair stimulation was small and the test 
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and the conditioned quanta of EEG overlapped, the 
Ä2 was measured after automatic subtraction of the 
single response from the paired one (Fig. lb). 
IfV--" 
Fig. 1. - Examples of retino-tectal quanta of EEG. 
a) The threshold stimulus evokes "all-or-nothing" 
responses. At the beginning there is the stimulus 
artefact; the thin arrow marks the presynaptic 
spike, the thick one marks the quantum of EEG, 
average of 10 responses. 1. a response to a single 
stimulus, 2. a response to pair stimulation, 3. 
a test response obtained by subtraction of 1. 
from 2. Calibration is 100 hV and 5 ms, negativity 
is down. 
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Pharmacological substances were delivered to the 
tectum by application (d-tubocurarine solution of 
0. 1 mmol/1) or by perfusion with the Ringer solution 
at the rate of 2.5, 5 and 9 ml/h (CdCl2 of 0.01 - 0.2 
mmol/1, ethanol of 2.5 % or 5 %) . As usual in 
experiments in vivo, we could not quantitatively 
determine the concentration of pharmacological 
substances in intercellular liquid. It is clear that 
this concentration is much lower in comparison with 
the applied or perfused solution. Due tb mixing the 
solution with spino-cerebral liquid and due to the 
possible arrest of the pharmacological substance by 
the endogenous extracellular ligands. 
Results 
Some examples of the action of biologically active 
substances on the synaptic transmission in the CNS 
are given. 
Specific N-cholinoblockator d-tubocurarine. 
Single quanta of EEG were diminished by d-tubocu­
rarine 2-3 times 10-20 min after application (Fig.2). 
The amplitude of the presynaptic spike was not 
sensitive to d-tubocurarine. 30 min rewashing of 
d-tubocurarine fully reestablished the quantum of 
EEG. When applied on paired quanta of EEG, d-tu­
bocurarine acts in two different ways. In some cases 
it diminishes the conditioned quantum of EEG stronger 
than the test one, consequently, in these cases 
d-tubocurarine augments the pair facilitation by 
0.5 - 0.9. In other cases the facilitation does not 
change, both quanta diminish proportionally. In the 
8 former cases the control conditioned quantum of 
EEG was large (Aj = 94 ± 5 pV, M ± S.E.M) but the 
facilitation was relatively small 
(f = 1.50 ± 0.02), in the 8 latter cases the opposite 
is true, Aj = 69 ± 7 pV, f = 1.99 ± 0.02. We term 
these cases weak and strong facilitating quanta 
respectively. When the action of d-tubocurarine was 
maximal we applied Ca2"1" (5 mmol/1) which eliminated 
the effect of d-tubocurarine in the group of weakly 
facilitating quanta; the Ca2 + only halfed the effects 
of d-tubocurarine on strongly facilitating quanta 
(Fig. 2b, 3). 
The frequency facilitation of synaptic trans­
mission is mainly caused by facilitated exocytosis 
of a neurotransmitter. When the control quantum of 
EEG, the control exocytosis, is dimished (enlarged) 
by raising extracellular Mg2+ (Ca2+), the pair 
1 0 4  
facilitation becomes stronger (weaker) [10]. Thus, 
we can say that enlarged frequency facilitation by 
d-tubocurarine of weakly facilitating quanta of EEG 
Fig. 2. - Effects of d-tubocurarine on the pairs of 
the quantum of EEG with weak (a) and strong (b) 
facilitation. 1. control, 2. 20 min after 0.1 
mmol/1 of d-tubocurarine, 3. 10 min after 5 mmol/1 
of Ca2 +  . Facilitation equals to 1.5 ± 0.1 (la); 
2.2 ± 0.3 (2a); 1.5 ± 0.1 (3a); 1.9 ± 0.1 (lb); 
1.8 ± 0.3 (2b); 1.8 ± 0.2 (3b). All the oscil­
lograms are averages of 64 responses, calibration 
is 100 mV and 5 ms. 
1 4  
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means that one of the causes of the diminishing of 
the amplitudes of these quanta by d-tubocurarine is 
its presynaptic action. This interpretation is 
supported by the fact of full elimination of 
du-tubocurrine blocade by high extracellular Ca2"1". 
We state that postsynaptic receptors in this case 
are not blocked by d-tubocurarine at all, the 
synapses are not N-cholinergic. When the quanta are 
strongly facilitating, when the diminishing of them 
by d-tubocurarine does not change the facilitation, 
the raised extrasellular Ca2 +  cannot fully eliminate 
the d-tubocurarine effect which is ascribed to 
N-cholinergic nature of postsynaptic receptors. 
It is clear that the method of registrating marked 
facilitating quanta of EEG enables us to demonstrate 
that d-tubocurarine may act presynaptically in the 
CNS, and that only a fraction of retino-tectal 
synapses in the frog is N-cholinergic contrarily to 
[ 1 8 ] .  _  
Neurotoxic Cd2 +  ions. 18 quanta of EEG studied 
when the tectum was perfused with CdCl2 solutions. 
The Cd2+ ions reversibly inhibited the quanta of 
EEG by 80 % on the average, while the presynaptic 
spikes were not appreciably changed. When the 
perfusion rate was raised up to 5 ml/h synaptic 
transmission was blocked by micromolar Cd2 +  (Fig. 
3). We noticed that synaptic delay increased by 0.15 
ms when the quantum of EEG was not yet fully blocked, 
this effect was statistically significant. Thus, 
Cd2+ acts presynaptically primarily by blocking Ca2+ 
channels in the CNS synapses in full agreement with 
its action mechanism firmly established on other 
preparations. The cadmium in industrial waste may 
be toxic for human population because of its action 
on the CNS, too. 
Ethanol. 14 quanta of EEG studied under perfusion 
of the Ringer solution with 0.22 or 0.54 mol/1 of 
ethanol. The control presynaptic spikes were of 
70 - 260 |J.V and the quanta of EEG were of 14 - 190 
HV. The lower concentration enlarged the spikes by 
6  -  1 0  %  a n d  t h e  q u a n t a  o f  E E G  b y  7 - 2 2  %  i n  
20 - 30 min, the larger concentration of ethanol 
enlarged the spikes by 11 - 38 % and the quanta of 
EEG by 14 - 34 7 o .  In the latter case the velocity 
of spike propagation decreased by 3 - 10 % judging 
from the latency of the spikes. All the effects were 
reversible. The simplest explanation of the changes 
of the spike amplitude and velocity would be the 
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3. - The effect of 10 pmmol/l of CdCl2on the amplitude of the spike (crosses) and 
of the quantum of EEG (circles), perfusion rate is 5 ml/h. Everly point is measured 
on the average of 10 responses. Insert - examples of responses of points a and b 
respectively. 1 - control, 2 - perfusion, 3 - wash. 
hyperpolarization of the membrane. The enlargement 
of synaptic potentials may be at least partly ex­
plained by the raised spike. 
In conclusion, the micromethod of the quantum of 
EEG in conjunction with frequency facilitation and 
ionic manipulations is useful in pharmacological 
research of central synapses, it enables investi­
gators to localize receptors of pharmacological 
substances in synaptic membranes, and to determine 
some features of the mechanism and specificity. 
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THE SEASONAL VARIATIONS OF BLOOD 
PRESSURE, PULSE RATE, CEREBRAL BLOOD FLOW 
AND BRAIN MONOAMINE CONTENT IN RABBITS 
M. Otter, A. Schotter 
Department of Pharmacology and Institute of Gen­
eral and Molecular Pathology, Tartu University 
Abstract 
In our previous studies a rather substantial 
difference between the initial values of the cerebral 
blood flow was found. On the other hand the brain 
monoamine content varies in different months of the 
year when studied. Comparative analysis of these 
parameters in rabbit brain was the aim of this paper. 
The content of noradrenaline (NA), dopamine (DA) 
and Serotonine (5-HT) in cortical and subcortical 
structures and the cerebral blood flow (LCBF), the« 
systemic arterial pressure (SAP) and pulse rate (PR) 
were learned. There were found seasonal variations 
in all parameters. A certain LCBF retardation in 
subcortical structures and cortex and the weakest 
effect of the stimulation was observed in May. There 
was a drop in SAP and some PR increase in the spring 
(April-May). Brain NA and 5-HT content showed 
seasonal changes with the lowest values near the 
winter months and reaching maximum in May as the PR 
does. Content of DA was low in May. So it seams 
possible that the LCBF in May can be explained by 
the decrease of brain DA at that time. The LCBF and 
the reactivity of cerebral microvessels depend on 
the monoamine content and show seasonal variability. 
Introduction 
Our previous research has proved the partici­
pation of the deep structures of the brain in the 
cerebral blood flow regulation. The locus in 
diencephalon has been found the stimulation of which 
causes microvessels' dilatation in the given region 
[17] and acceleration of local cerebral blood flow 
(LCBF) [18], while the systemic arterial pressure, 
the pulse rate and breathing do not change. 
Consequently, if the systemic factors regulating 
cerebral blood flow are stable, the regulation of 
cerebral blood flow will be carried out by means of 
no 
intracerebral mechanisms. As we know, the reactivity 
of brain has a mosaic character [12], hence the 
appearance of reacions having different directions 
and strengths in varied experiments. Alongside with 
that our attention was paid to a rather substantial 
difference between initial values. The question of 
the role of seasonal fluctuation arose. The present 
paper deals with some aspects of this problem. 
Methods 
Our work is based on the studies of one animal 
species - the rabbit, and they a lasted all the yar 
round, except summer. The rabbits involved were kept 
under similar vivarium conditions; they were given 
similar food. For this purpose a total of almost 
300 rabbits (both male and female) in the age of 
less than one year were used. The research was 
carried out during 13 years in 3 stages. 
Stage I: the systemic arterial pressure (SAP) 
and pulse rate (PR) were measured. For that purpose, 
in the animals with stereotaxically implanted 
electrodes, under urethan narcosis (1 g/kg i.m.) a 
cannula was introduced into the femoral artery. The 
cannula was connected to a hydrargyrum manometer 
via a polyvinyl tube. The SAP and PR were measured 
continuously during 5 min. The variations of the 
data of the reference group were by the month compared 
with those of the experimental group, whose brain 
structures had been electrically stimulaled (0.5 
ms, 60 Hz, IV, 5 x 50 s). 
Stage II: the local blood flow (LCBF) of an animal 
was measured by means of hydrogen clearance [16] 
during wakefulness without any premedication. Blood 
flow was measured simultaneously in the stimulated 
structure and in the precentral region of the 
cerebral cortex with previously implanted platinum 
electrodes. Stimulation (0.5 ms, 60 Hz, 2-4 V, 33 
s) was conducted via a nichrome electrode. Before 
the experiment, the animals were subjected to a 
10™day adaptation period. The experiments took place 
at noon under similar conditions. The LCBF initial 
values and those obtained after stimulation in 
different months were compared. 
Stage III: the observations concerning the 
variations of brain monoamine content in rabbits 
under unique experimental conditions were carried 
out in 1972, 1973, 1981 and 1982. The content of 
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bioactive monoamines noradrenaline (NA), dopamine 
(DA) and Serotonine (5-HT) in cortical and sub­
cortical structures of the rabbit was learned. 
The concentrations of NA, DA and its chief 
metabolite homovanillic acid (HVA) were assayed 
spectrofluorimetrically according to the methods 
described by M.K. Schellenberger and J.H. Gordon[8], 
and modified by P.F. Spano and N.H, Neff [9]. The 
serotonin (5-HT) and its metabolite 5-hydroxyin~ 
doleacetic acid (5-HIAA) concentrations were de­
termined spectrofluorimetrically by the method of 
G. Curzon and A. Green [3]. 
For biochemical studies, the rabbits were de­
capitated and their brain structures were immedi­
ately frozen in liquid nitrogen. Minimally two weeks 
prior to each series of studies the animals were 
kept at a nearly constant temperature (20 °C) . They 
were given food and water ad libitum and they were 
exposed to 12:12 hr regimen of alterating darkness 
and artificial light [14, 15]. The experiments were 
carried out in groups consisting of 2-6 animals. 
Results and discussion 
The initial values of SAP mostly varied within 
90-120 mm Hg thus yielding the average value in a 
year 105 ± 1.4 mm Hg. The PR initial values for the 
same animals mostly 200-220 and the annual average 
- 210 ±3.9 beats per minute. 
When comparing the monthly initial values of the 
SAP and PR we found that spring data tended to differ 
those of autumn and winter and from the average year 
value. The comparison of the average data with those 
of the first half of the year (table 1) shows that 
there is a drop in blood pressure and some pulse 
rate increase in the spring. 
Different nuclei of the thalamus, hypothalamus, 
septum and amygdala, as well as the ventral and 
dorsal hippocampus and the globus pallidus were 
electrically stimulated (III. 1). 
The stimulation of the deep structures of the 
brain with the parameters given does not bring about 
any SAP and PR changes (table 2). 
The initial values of LCBF varied in case of 
different rabbits. A certain variability was ob­
served in one and the same rabbit in different 
experiments. The majority of the LCBF was situated 
in the range of 40-80 ml/100 g/min. 
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Table 1 
The systemic arterial pressure (SAP) and the 
pulse rate (PR) changes from January to May (I -
V) 
The months SAP (mm HG) PR (beats per 
minute) 
I 109. 1 208. 1 
II 104.0 205.0 
III no data no data 
IV 97. 9 212.8 
V 91.5 220. 9 
As in the cases of SAP and PR, there are seasonal 
differences in the LCBF values. Thus, both in the 
cortex and in deep structures a certain LCBF 
retardation is observed in May (table 3). 
Stimulation has resulted in the LCBF acceleration 
in deep structures and in both changes - increase 
or decrease of LCBF - in the cortex. The smallest 
effect of the stimulation is observed in May. 
Consequently, in spring the SAP and LCBF of 
rabbits drops, while their pulse rate increases a 
little. At the same time, the reactivity of the 
brain vessels to a local irritation tends to de­
crease. The phenomen may have several reasons. 
In order to establish the probable endogenic 
causes of the changes in cerebral blood flow in 
spring, we compared the results of our experiments 
with the dynamics of the monoamines' contents of 
the brain. The content on monoamine varies seasonally 
Ü, 14, 15]. 
Some autors have shown that one of the purposes 
of seasonal variations of physiological parameters 
of experimental animals kept in constant tempera­
ture, light and food conditions are circa annual 
variations of geomagnetic fields. The geomagnetic 
storms occur usually during autumn and spring months 
[5]. The basic role of their structural-functional 
performances is influencing on neuroendocrino­
logical regulation mechanisms. 
The possible role of brain monoamines in the 
control of different aspects of the animal car­
diovascular system has been extensively discussed 
in the literature [1, 6, 7]. 
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Table 2 
The systemic arterial pressure (SAP) and the pulse rate (PR) before and after the 
stimulation of the deep structure of the brain 
The stimulated 
structures 
SAP (mm Hg) PR (beats per minute) 
Before stimu­
lation 
After stimula­
tion 
Before stimu­
lation 
After stimula­
tion 
Thalamus 107 ±5.7 104 ±4.7 213 ± 6.9 201 ± 4.0 
Hypothalamus 103 ± 4.0 99 ± 2.2 209 ± 4.9 219 ±7.1 
Septum 109 ± 6.4 105 ±6.1 192 ± 1.4 185 ± 5.6 
Amygdala 104 ± 6.4 102 ±6.5 216 ± 2.8 213 ± 3.9 
Hippocampus 99 ± 2.0 95 ± 4.2 208 ± 6.6 198 ± 4.2 
Globus pallidus 104 ± 1.7 101 ± 1.4 211 ± 7.2 209 ± 9.6 
All together (n = 96) 405 ± 1.4 101 ± 1.4 210 ± 3.9 209 ± 5.9 
Table 3 
The local cerebral blood flow (LCBF) changes in different months (I - V - the months 
from January to May) 
The months LCBF of the deep structures LCBF of the cortex (ml/100 g/min) 
Before stimula­
tion 
After stimula­
tion 
Before stimula­
tion 
After stimulation 
I 67. 6 74.2 87.8 101.3 
II 79. 7 113.4 103. 6 124.6 
III 85.6 120. 1 no dates 
IV 87.3 101. 6 91. 1 77.3 
V 67. 1 70.4 46. 9 46.3 
Note! The deep structure in these experiments are thalamus hypothalamus and septum. 
From a methodological point of view, the most 
convenient approach to this problem seems obviously 
to be the search for a clearcut causal correspondence 
between a given pattern of cardiovascular processes 
and its specific biochemical correlate. Brain NA 
showed marked seasonal changes with the lowest values 
near the winter months (Table 4). From this time it 
began to increase, reaching its maximum in May. 
Thereafter a progressive and significant lowering 
was noticed. NA has got a calorigenic effect. The 
seasonal variations of muscular energetics by 
seasonal variation of pulse rate were shown [4]. 
The results of our experiments (Table 4) show 
that the content of 5-HT in the rabbits brain cortex 
has peak values in January (during the first weeks) 
and in May. The dynamics of the content of indolamines 
is connected with the variability of the functions 
of CNS [1]. Reciprocally to the seasonal variations 
of indolamine melantonine is varying the content of 
gonadotropic hormones (whose peak value is reached 
in March-April) [6]. The content of 5-HT in our 
experiments during these months was also low. 
The variation of heart rate, blood pressure, 
minute volume etc. has a rather regular character 
with maximal values in winter [13]. In our ex­
periments the SAP in January was higher than in May. 
The activation of heart rate in connection with O2 
consumption in response to exercise is higher during 
winter months [4]. 
As it is well known, the basic physiological 
patterns of mammals are controlled by two opposite 
somato-vegetative coordinating structures of the 
CNS. Those behavioural states characterized by a 
marked expenditude of energy are postulated to be 
modulated by the so called "ergotropic system", 
adrenergic in nature [7, 11]. They usually involve 
a high degree of responsiveness to external 
stimulation, sympathetic predominance and increased 
motor activity. On the other hand, physiological 
states such as sleep and winter rest, which are 
common traits in energy storage, could be regulated 
by another "trophotropic system". 
The functional activation of sympathico-adrenal 
system is increasing in autumn and winter months. 
This is concerned with noradrenaline concentration 
change and with the increase of heart rate. During 
winter, when animal behaviour and life-processes 
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Table 4 
Variability of the mean concentrations of serotonin (5-HT), noradrenaline (NA), do­
pamine (DA) and dopamines metabolite HVA in ng/g of wet tissue of the rabbits brain 
cortex during the first half of the year 
Months 5-HT NA DA HVA 
I 0.60 ± 0.06 0. 16 ± 0.01 0.38 ± 0.07 о
 
ы
 
Ы
 
H- о
 
о
 
II 0.47 ± 0.04 0.17 ± 0.01 0.41 ± 0.05 0.28 ± 0.02 
III 0.33 ± 0.02 0. 17 ± 0.02 0.72 ± 0.09 0.43 ± 0.05 
IV 0.37 ± 0.05 0. 19 ± 0.03 0.55 ± 0.06 0.49 ± 0.05 
V 0.66 ± 0.08 0.31 ± 0.04 0.44 ± 0.04 0.64 ± 0.07 
VI 0.46 ± 0.06 0.24 ± 0.02 0.51 ± 0.05 0.48 ± 0.03 
clearly demonstrate the predominance of energy-
saving mechanisms, with lower motor activity an 
important decrease in the O2 consumption and in 
general metabolic rate associated with an increased 
storage of carbohydrate, fat and proteins in dif­
ferent organs is noted. In this period arterial 
hypotension and a lowered vasomotor responsiveness 
are observed [7]. All these features suggest p r i m a  
facie a functional preponderance of parasympathic 
mechanism. 
Conversely, the O2 consumption and the general 
endocrine - metabolic rate, as well as circulatory 
responses are greatly enhanced during mating and 
estivation. These facts, in the phase with the 
significant and opposite displacement in the DA and 
5-HT brain content again make consider a possible 
causal relationship between monoamines and car-
dio-vascular patterns in this period. 
As it is known, the vasodilatation has more a 
DA-ergic nature and vasoconstriction takes place as 
a result of NA-ergic activation. So it seems possible, 
that the low LCBF in May can be explained by the 
increase of brain NA and decrease of brain DA at 
that time. Decreasing SAP in spring may be in 
connection with the character of the anaesthesia, 
which is correlated with the increased concentra­
tions of NA and 5-HT in the brain [11, 13]. The 
practically constant SAP and PR during the stimu­
lation are due do the weak stimulus in these ex-
perimente (1 V) and to the lowered reactivity of 
the brain in narcosis. 
It is concluded that the LCBF and the reactivity 
of cerebral microvessels depend on the monoamine 
content of the brain and show seasonal variability. 
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THE PROGRESS IN TEACHING PHARMACOLOGY 
IN TARTU UNIVERSITY DURING PERIOD 
1 9 4 4 - 1 9 8 9  
L. Nurmand 
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Abstract 
A short survey of the development of teaching in 
pharmacology in Tartu University during the period 
1944-89 is given. During this period the amount of 
pharmacological information increased nearly two­
fold but the number of hours for its presentation 
remained practically unchanged (150-170 hrs.). 
Beside the publication of text-books and many 
teaching aids it was necessary to revise all system 
of lectures, practical training and testing of 
students knowledge. At last a renewed teaching system 
was established. 
Introduction 
During the Second World War most of the apparatus 
and glassware of the chair of pharmacology had got 
lost. Therefore the teaching process began almost 
from zero. In 1944/45 there were one professor (Georg 
Kingisepp) and two assisting students from the 5th 
course. 
The lectures were read to the students of medical, 
stomatological, pharmaceutical and veterinary 
faculties. There were no heating, gas or water, no 
laboratory animals or reactives. The lack of them 
produced difficulties in practical laboratory work. 
The vivarium was to be reconstructed, 150 frogs were 
caught and white mice and guinea pigs for repro­
duction were borrewed. The drug collection was 
reorganized on the basis of Soviet Pharmakopoea. 
During summer one of the assistants had to collect 
medical plants for demonstration preparations. It 
took 2-3 years to normalize the process of training 
in the department. 
Until 1948 the teaching program was compiled in 
the department. In 1948 and in 1951 the all-union 
programs in pharmacology were issued. In these 
programs a special stress was laid on the priority 
and achievements of Soviet and Russian medical 
121 
16 
science. The equipment of the department did not 
allow to carry out practical trainings on a con­
temporary level. Only the simpliest experiments, 
which did not need any laboratory animals could be 
carried out by students. In 1952, the vivarium was 
reconstructed and became possible to use laboratory 
animals. In 1952 the teaching staff became more or 
less stable. In the following years the equipment 
and materials were obtained. New apparatus for 
research and training was acquired. In 1965 an 
additional room of the department was reconstructed 
for experimental laboratory work, in which all tables 
were equipped with water, gas, compressed air and 
electricity. Three textbooks of pharmacology (1948, 
1963 and 1982), also some teaching aids and syl­
labuses were published. After the formation of the 
Estonian Agricultural Academy in the 50-s the 
teaching of pharmacology to veterinary students was 
finished. As a new subject the clinical pharmacology 
was introduced. In 1964/65 and 1965/66 only a few 
chapters were read to 5th year students as an optional 
discipline. Beginning from 1971 this course became 
a regular one. Lectures on several topics were 
divided between the teachers from pharmacology 
department and clinical disciplines. Clinical 
pharmacology was read to 6th year students of 
medicine during 66-76 hrs. In 1981 by a decree of 
the USSR Ministry of Health Tartu University was 
determined as an experimental basis for teaching 
clinical pharmacology. To the lectures seminars were 
added. Refresher courses in pharmacology for 
postgraduate pharmacists were started in the 60s. 
From 1976, on the basis of department of pharmacology 
refresher courses in clinical pharmacology and 
pharmacotherapy for postgraduate physicians were 
organized. 
Lectures 
The course of pharmacology has traditionally 
consisted of lectures and laboratory training. 
During the period from 1944 to 1989 considerable 
changes in the contents and form of teaching process 
have taken place. In first two decades it was possible 
to discuss the more important preparations indi­
vidually, to draw attention on their dosage and 
combinations used, also to present the most in­
teresting experimental data. Later, with the growth 
of a number of drugs, and appearance of principally 
new information about mechanisms of action, it became 
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impossible to present such detailed information. 
Beginning of 1972 professor Lembit Allikmets was 
elected the head of department. It became necessary 
to change the way of presentation of the growing 
material. In these years a new system of presentation 
was worked out. It was put into proper form and 
several teaching materials were issued by the 
University Press (1972, 1977, 1981, 1987). The 
classification of drugs in latin also gave the 
students a full survey of the whole pharmacological 
system. In lectures a more detailed analysis of 
pharmacological properties of a whole drug group 
could be present instead of description of single 
preparations. A more or less certain system for 
presentation of the material was proposed: a short 
historical survey, general characteristics of the 
whole drug group, data about chemical structure, 
pharmacokinetics, mechanism of action, therapeutic 
and side effects, therapeutic principles and 
toxicity. In such a scheme it was possible only to 
compare the main properties of single preparations. 
The publication of a textbook (1982) in Estonian 
and textbooks in Russian enabled not to read the 
whole course but to concentrate on the most topical 
problems. The students had to work through the themes 
left out on their own. This part of the course has 
been increasing from year to year and in 1988/89 it 
was about 30-35 % of the whole material. As the role 
of student's individual work has increased, the 
necessity for effective system of testing their 
knowledge arose. During the period considered the 
use of visual aids in lectures has undergone con­
siderable modifications. In the 40s and 50s the 
lectures were illustrated mainly by tables, es­
pecially chemical formulas drawn by the teaching 
staff. In the lectures drugs and pharmaceutical 
preparations were also demonstrated. Demonstration 
of experiments on animals was also of importance, 
although the auditorium of the Old Anatomical Theatre 
was not suitable for it. The lecture demonstrations 
were carried out either during the lecture time or 
concentrated on the spring term in hours for con­
sultations. The number of lecture demonstrations 
was maximal in 1955-1957, then in decreased and 
lecture demonstrations were abandoned in the 60s. 
Obtaining of contemporary projecting equipment in 
70s permitted us to use slides for lecture illus­
tration. A wide collection of slides was established. 
Since then the demonstration of slides and trans-
parents has become an inseparable part of lectures. 
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The film-projecting apparatus allowed to demonstrate 
films. The increased importance of projection ma­
terial in lectures have supersede tables. 
Practical (laboratory) training 
The role of laboratory training in teaching of 
pharmacology has been used in order to introduce 
the methodological aspects of pharmacology and to 
work out the prescribing skill. In order to solve 
these assignements several different methods were 
used, and at last the teaching concept was changed. 
The traditional laboratory training in pharmacology 
until the mid 70s was as follows. The students worked 
in groups of 5-6, later 3-4. The laboratory class 
began with an introduction in which beside theor­
etical aspects the methodology of definite ex­
periments was introduced by the teacher. After that 
the students carried out experiments on laboratory 
animals or on themselves. The results were proto-
colled. The training was finished with a conclusion, 
made by the teacher. This scheme was improved with 
the issue of methodological instructions, which were 
completed as a teaching aid in 1975. It helped to 
spare time. The conclusions became more detailed 
and were combined with the frontal questioning of 
the students. The role of testing students knowledge 
in theoretical topics was increased. In the first 
after-war years there was no control of theoretical 
knowledge, but later more and more attention has 
been concentrated on it. Inspite of its importance 
it began to limit the time for practical experimental 
work. Regardless of the improvements made,, the 
classical scheme of practical training did not give 
satisfactory results. The preparation of experiments 
and their practical realizing took too much time. 
The students' attention was pointed principally on 
the technical aspects of the experiments, not so 
much on the results achieved. The results of the 
experiments, which were rather primitive from 
contemporary scientific stand-points, did not give 
any expected results in 100% of cases. Not seldom 
the artefacts deformed the correct results. All this 
made it more difficult for the teacher to form a 
correct conclusion and often in was not in accordance 
with his pedagogical principles. All this diminished 
the value of practical training. Taking it all into 
account the classical scheme of practical training 
was modified. Beside experiments seminars were 
introduced and by the end of the 70s the role of 
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ezperimental work practically lost its importance. 
In seminars papers written by the students were 
discussed. The discussion was with frontal ques­
tioning. Later on a new scheme of practical training 
still developed. The concept of training was also 
changed. It became clear that it was practically 
impossible to teach the students the contemporary 
pharmacological experimental methodology, moreover, 
for a student and especially for a practising 
physician the knowledge of only pharmacological 
methodology is not sufficient. It is important to 
teach and develop the pharmacological mode of 
thinking. A thesis was formulated: a student has to 
acquire the skill of choosing a proper drug con­
sidering all conditions of the assignement, also 
the pharmacokinetic, pharmacodynamic and toxico-
logical properties of the drug; the student has to 
know how to prescribe the drug chosen. In order to 
develop thinking and analizing skills several 
methods were tried out, starting with the analysis 
of problematic slides, as it was done in the First 
Moscow Medical Institute. This system did not suit 
the teachers of the department and it was soon 
abandoned. The training of prescribing skills was 
carried out parallel to practical training. 
In the first decades until the publication of a 
special teaching aid (1975), the prescribing of 
drugs was lectured during practical training hours. 
Till 60s these "minilectures" took place trough the 
whole years, later on they were concentrated at the 
beginning of the autumn term. During the laboratory 
training the students had to prepare the simplest 
prescribing forms (powders, pills, ointments, 
solutions ets. ). Special practical trainings of 
prescribing skills were carried out several times 
in both terms. After publication of the teaching 
manual (1975) there was nõ need for those lectures 
any more and the time spared could be used for 
practical writing of the prescriptions. From the 
1961/62 academic years in the autumn and spring 
termas special prescribing tests were introduced. 
The student had to write 5 prescriptions without 
any mistakes on condition that the spelling of the 
drug name and the dosage were given. As the students 
could usually manage it only after 4 or 5, seldom 
10 or more attempts, the prescribing art considerably 
improved. In order to help the students prepare for 
these tests, a collection of prescribing tests was 
published (1976). This collection included not only 
test assignements but also the assignements basing 
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on indications, which were later included into spring 
term tests. The assignements basing on indications 
of principal drug effect were also analized and 
solved in practical training time, their importance 
gradually increased and the analizing tactics im­
proved. The test collection was republished (1982, 
1986). To the beginning of the 80s a standard scheme 
for solving such situational assignements was fi­
nally worked out. From this time the solving of 
situational tasks became a main part in practical 
training beside written papers and discussion. In 
the last years the solving of situational tasks has 
to be done as follows: 
- the student words the exact effect needed; 
describes all mechanisms enabling to reach it; 
names all drug groups and drugs having the 
effect needed; 
while choosing the appropriate drug the student 
compares the pharmacokinetics, main and side 
effects of each drug in question; 
looks up the prescribing form, dosage, dosing 
schedule of the drug chosen; 
writes the prescription 
Such analysis can be made either individually or in 
groups, also teaching aids or text-books can be 
used. The experience of last years shows that this 
scheme stimulates the students' thinking and 
mobilizes their passive knowledge. 
The testing of students' knowledge 
The final level of students' knowledge is checked 
on examinations in the spring term. This is 
traditionally an oral examination which is based on 
question slips, in addition to that the student has 
to write 2 prescriptions. This scheme has existed 
practically without any principal changes through 
all the period in question. Considerable changes 
have taken place in the current testing system. 
Until the last 2 years rather substantial testing 
took place each term. These tests were carried out 
in different years either orally or in written form. 
Up to the beginning the 1970s colloquiums and 
prescribing tests took place each term. During the 
last 2 years (1987/88 and 1988/89) at students' 
request the total number of colloquium has been 
increased to 7 and they have been shortened. The 
teaching process was planned so that the lectures 
and practical trainings were concentrated on certain 
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1961-70 1971-80 1981-89 1951-60 Years 1945-50 
Experiments 
Tables 
Slides 
Transparents 
Films 
Experiments 
Prescribing tests 
Situational tasks 
Problematic 
slides 
Current tests 
Written papers 
Fig. 1. Methods used in teaching pharmacology in Tartu University during period 1944-1989. 
topics, each such cycle finished with consultations 
and with a colloquium. Thr colloquium included also 
problems worked trough by the students themselves. 
In the middle of 60s in practical training regular 
tests were introduced. The form of these tests has 
undergone certain changes. At one time programmed 
tests were used, at the other either oral questioning 
or written tests applied. Written tests proved to 
be the most effective ones, permitting to assess 
both theoretical knowledge as well as the prescribing 
skills of the students. The questionnaires for the 
tests have been issued regularly (1979, 1982, 1988). 
The tests were timed at begin of training in order 
to check the previous level of knowledge or after 
training to fix the obtained information. Each 
version has both positive and negative aspects. The 
fact that the valuable time of teaching must be 
wasted on tests is the most negative side of their 
both. Testing with accompanying analysis takes at 
least 15-20 minutes which compared to the 90 minutes 
of practical training time in the spring term is 
apparently too much. In the last 2 years both at 
students' request and considering the increase of 
the number of colloquia these regular tests have 
not been used any more. The knowledge control was 
limited to current questioning during trainig time. 
As it is shown the teaching process in the chair 
of pharmacology of Tartu University has continually 
developed. Finally the concept of lectures and 
practical trainings, and their contents and forms 
have become more contemporary and, we hope, also 
more effective. 
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ИЗМЕНЕНИЕ ПЕРИФЕРИЧЕСКИХ БЕНЗОДИАЗЕПИНОВЫХ 
РЕЦЕПТОРОВ («3) КРОВЯНЫХ КЛЕТОК КРЫС ПРИ 
РАЗЛИЧНЫХ МОДЕЛЯХ СТРЕССА: ВЛИЯНИЕ 
ТРАНКВИЛИЗАТОРОВ НЕБЕНЗОДИАЗЕПИНОВОГО РЯДА 
Л.К. Ряго, А.Ю. Адояан. П.Л. Покк 
Р е з ю м е  
В настоящей работе изучалось изменение пери­
ферических (w^) бензодиазепиновых рецепторов 
(БДР) при некоторых моделях стресса. 
Как показали опыты, электроболебое раздраже­
ние значительно понижало связывание ^ Н-диазепама 
с тромбоцитами. Плавательный стресс и процедура 
хронической инъекции повышали количество мест 
связывания ^ Н~Ро 5-4864 как на тромбоцитах, так и 
на лимфоцитах. 
Транквилизаторы небензодиазепинового ряда, 
фенибут и буспирон, в опытах in vivo по-разному 
влияли на БДР кровяных клеток. Так, фенибут 100 
мг/кг значительно повышал аффинность связывания с 
^Н-Ро 5-4864 и проявлял тенденцию к понижению 
числа мест связывания радиолиганда на тромбоци­
тах. Буспирон (5 мг/кг) не изменял параметров 
связывания^Н-Ро 5-4864. Предварительное введение 
фенибута (100 мг/кг) предупреждало эффект плава­
тельного стресса на БДР как на тромбоцитах, 
так и на лимфоцитах. Буспирон (5 мг/кг) не влиял 
на связывание ^Н~Ро 5-4864 БДР тромбоцитов при 
плавательном стрессе, однако в этих условиях он 
понижал связывание радиолиганда на лимфоцитах 
крови крыс. 
В работе обсуждаются возможные механизмы 
изменения БДР кровяных клеток при разных 
моделях стресса. Предполагается возможность ис­
пользования БДР кровяных клеток как чувствитель­
ный маркер определения эмоционального статуса. 
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ПЕРИФЕРИЧЕСКИЕ МЕСТА СВЯЗЫВАНИЯ БЕНЗОДИАЗЕПИНОВ 
НА ТРОМБОЦИТАХ И ЛИМФОЦИТАХ КРЫСЫ: ВОЗДЕЙСТВИЕ 
ГАМК-ЕРГИЧЕСКИХ ВЕЩЕСТВ 
А.Ю. Адояан, Л.К. Ряго 
Р е з ю м е  
По современным представлениям агонисты ГАМК 
рецепторов не изменяют параметров связывния 
лигандов периферических бензодиазепиновых ре­
цепторов i n  v i t ro .  
В настоящей работе нами изучалось влияние 
мусцимола, дипропилацетата и фенибута на взаимо­
действие бензодиазепиновых радиолигандов с пери­
ферическими местами связывания (ПМС) бензодиазе-
пинов (БД) in vivo. Исследование проводились на 
интактных тромбоцитах и лимфоцитах мечеными аго-
нистами БР [^Н]Ро 5-4864 или [^Н] диазепамом. Как 
показали результаты опытов, не только агонист 
ГАМК рецепторов мусцимол, а также дипропилацетат 
и фенибут повышали аффинность периферических БД 
мест связывания как на тромбоцитах, так и на 
лимфоцитах. 
Число БД мест связывания на клетках крови не 
изменяется под воздействием ГАМК-ергических ве­
ществ in vivo. В работе обсуждается модулирующая 
роль ГАМК-ергических веществ на ПМС БД кровяных 
клеток. 
РОЛЬ ПОТЕНЦИАЛ-ЗАВИСИМЫХ КАНАЛОВ КАЛЬЦИЯ В 
РАЗВИТИИ АБСТИНЕНЦИИ ПОСЛЕ ОТМЕНЫ ХРОНИЧЕСКОГО 
ВВЕДЕНИЯ ДИАЗЕПАМА 
A.M. Жарковский, A.C. Шаврин, Т.А. Жарковская, 
К.З. Черешка 
Р е з ю м е  
В экспериментах на крысах самцах хроническое 
введение диазепама (10 мг/кг/день, в/бр., 30 
дней) вызывало развитие спонтанного абстинентного 
синдрома. Введение этим животным антагониста бен­
зодиазепиновых рецепторов CGS 8216 (5 мг/кг, 
в/бр. ) вызывало дополнительное усиление признаков 
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абстиненции. Антагонисты каналов кальция верапа-
мил (10 мг/кг) и нифедипин (5 и 10 мг/кг), 
вводимые за 30 мин до CGS 8216, ослабляли призна­
ки абстиненции. После отмены хронического введе­
ния диазепама у животных наблюдалось снижение 
связывания [^Н]нитрендипина и одновременно увели­
чение захвата ^-5Са^+ синаптосомами в условиях 
деполяризации. Повышенный захват после от­
мены диазепама угнетался добавлением диазепама (1 
мкМ) или верапамила (1 мкМ) в среду инкубации. В 
этих концентрациях вещества не влияли на захват 
^->Са2+ синаптосомами контрольных животных. Пред­
полагается, что повышение захвата кальция через 
активированные потенциал-зависимые каналы может 
вызывать развитие 
признаков абстиненции. 
ЗЕВАНИЯ У КРЫС, ВЫЗВАННЫЕ АНТАГОНИСТАМИ КАЛЬЦИЯ 
A.M. Жарковский, К.3. Черешка, Г.Э. Цеберс 
Р е з ю м е  
При системом введении антагонисты кальция 
вызывают зевания у крыс. По силе действия вещест­
ва располагаются следующим образом: нифедипин = 
флунаризин > верапамил = дильтиазем. Поскольку 
флунаризин и верапамил вызывают зевания при их 
введении в желудочки мозга, следовательно, можно 
предполагать, что зевания, вызванные антагониста­
ми кальция, центрального происхождения. 
Совместное введение дофаминомиметиков апо-
морфина и квинпирола или агониста М-холинорецеп-
торов пилокарпина с антагонистами кальция вызы­
вает повышение этого поведенческого эффекта. 
Нейролептики сульпирид, галоперидол и SCH-23 390, 
а также антагонист М-холинорецепторов скополамин 
дозозависимо угнетают зевания, вызванные нифеди-
пином. Есть основание предполагать, что в меха­
низме возникновения зеваний задействованы потен­
циал-зависимые каналы кальция. 
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ОСОБЕННОСТИ МЕХАНИЗМА ГИПОТЕНЗИВНОГО ДЕЙСТВИЯ 
ЦИКЛИЧЕСКИХ АНАЛОГОВ АНГИОТЕНЗИНА II 
И БРАДИКИНИНА 
В.В. Голубева, М.П. Раткевича, Е.А. Порункевич, 
В.Е. Клуша 
Р е з ю м е  
Нами показано участие гистаминового и серо-
тонинового компонентов в механизме гипотензивного 
действия модифицированных циклических аналогов 
ангиотензина II и брадикинина. Блокада Н^-ре­
цепторов дифенгидрамином и ингибирование синтеза 
серотонина парахлорофэнилаланином достоверно 
уменьшает гипотензивныи эффект, вызванный цикло-
пептидами. 
Найденная нами способность циклического ан­
гиотензина и циклического брадикинина высвобож­
дать 
гистамин из перитонеальных тучных клеток 
крыс в экспериментах in vitro, являясь еще одним 
доказательством в пользу участия гистамина в 
гипотензивном действии циклопептидов, дает воз­
можность предполагать, что именно тучные клетки 
могут быть 
клетками-мишенями для циклопептидов. 
Стабилизация мембран тучных клеток инталом 
полностью предотвращает развитие гипотенозного 
эффекта малых доз циклических ангиотензина и бра­
дикинина (2 и 10 мкг/кг соответственно) и умень­
шает продолжительность гипотензивного действия 
больших доз циклического ангиотензина и брадики­
нина (5 и 50 мкг/кг соответственно). Добавление 
интала в концентрации 0,1 мг/мл в инкубационную 
среду на 50 % снимает высвобождение гистамина 
циклическим брадикинином в дозе 10~^М из перито­
неальных тучных клеток крыс в экспериментах i n  
v i  t r  о .  
Таким образом совокупность полученных данных 
дает возможность рассматривать циклические произ­
водные ангиотензина и брадикинина как соединения 
со своеобразным механизмом действия - способнос­
тью высвобождать гистамин и серотонин из тучных 
клеток крыс. 
Обсуждается возможность высвободить другие 
вазоактивные субстанции из тучных клеток крыс 
циклическими производными вазоактивных пептидов. 
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ВЛИЯНИЕ СИСТЕМНОГО ВВЕДЕНИЯ АГОНИСТОВ ХЦК-8 НА 
ПАРАМЕТРЫ СВЯЗЫВАНИЯ РЕЦЕПТОРОВ В ЦНС 
Я. Харро, Р.-А. Кийвет, М. Пыльд, А. Ланг, 
Э. Васар 
Изучалось влияние системного введения церу-
леина (0,1 - 10 мкг/кг) и пентагастрина (0,5 - 50 
мкг/кг) на бензодиазепиновые, опиатные в ГАМК-
рецепторы в мозге крыс. Показано, что ХЦК-8 аго-
нисты могут вызывать изменения в параметрах свя­
зывания меченых лигандов этих рецепторов. Введе­
ние крысам церулеина и пентагастрина в низких 
дозах понижало число бензодиазепиновых рецеп­
торов в фронтальной ком и повышало это число в 
гиппокампе. Связывание ^ Н-ГАМК в мембранах гиппо-
кампа тоже повышалось. Введение пентагастрина в 
более высоких (седативных) дозах изменяло пара­
метры связывания с опиатными рецепторами. Влияние 
нейропептидов на параметры центральных рецепторов 
медиаторов при системном введении может быть 
основой поведенческих эффектов этих веществ, oi— 
раниченно проникающих через гематоэнцефалический 
барьер. 
NMDA-РЕЦЕПТОР: ОСНОВНЫЕ ИТОГИ ИЗУЧЕНИЯ И 
ПЕРСПЕКТИВЫ ИСПОЛЬЗОВАНИЯ АНТАГОНИСТОВ В КЛИНИКЕ 
С.А. Гутников 
Р е з ю м е  
Аминокислоты опосредуют около половины всей 
синаптической передачи в мозге млекопитающих. Из 
рецепторов возбуждающих аминокислот наиболее изу­
чен К-метил-(1-аспартатный (NMDA) рецептор. В об­
зоре рассматривается структура комплекса NMDA-pe-
цептор/катионный канал, агонисты и антагонисты, 
их 
эффекты у животных. Обосновывается возможность 
использования антагонистов для лечения эпилепсии, 
гипоксии (в т.ч. перинатальной), инсульта, нейро-
дегенеративных заболеваний (болезнь Альцгеймера, 
хорея Геттингтона, боковой амиотрофический скле­
роз) . Высказывается предположение об участии 
NMDA-рецепторов в патогенезе психозов и лекарст­
венной зависимости. 
1 8  
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УРОВЕНЬ ОЛИГОМЕРИЗАЦИИ - РЕГУЛЯТОРНЫЙ ФАКТОР 
ФУНКЦИОНИРОВАНИЯ ТРАНСПОРТНЫХ (И РЕЦЕПТОРНЫХ) 
БЕЛКОВ 
М. Цильмер, Т. Салум, Т. Вихалем, Т. Куллисаар, 
Э. Карелсон, Л. Тяхепыльд 
Р е з ю м е  
Показано, что кооперативность Na + и К+ Na, 
К-АТФазы мозга зависит от степени олигомеризации 
фермента и что лиганд-белковые взаимодействия 
устанавливают уровень олигомерной структуры фер­
мента. Предполагается, что один из биологических 
механизмов генеза патологических процессов с 
повышенным внутриклеточным содержанием ионов Na 
(опухолевые болезни и гипертония) связан с нару­
шением на высшем уровне олигомеризации (аллосте-
рически свойств) Na, К-АТФазы, которая приводит к 
уменьшению положительной кооперативности связыва­
ния ионов Na. Нарушение уровня олигомеризации 
транспортных и рецепторных белков связано с раз­
витием патологических процессов. 
ЭЛЕКТРОФИЗИОЛОГИЧЕСКИЙ МЕТОД ДЛЯ ИЗУЧЕНИЯ 
ФАРМАКОЛОГИИ СИНАПСОВ НА УРОВНЕ ОТДЕЛЬНОГО 
ПРЕСИНАПТИЧЕСКОГО ВОЛОКНА 
Р. Блистрабас, А. Гутман, А. Курас, А. Мицкис, 
Н. Чусайновиене 
Р е з ю м е  
В работе дана характеристика прямого 
неповреждающего метода для изучения фармакологии 
синапса. Метод основан на регистрации квантов 
ЭЭГ, т.е. потоков моносинаптических потенциалов, 
генерируемых отдельными пресинаптическими волок­
нами. Метод представлен на примере эксперимента 
проведенного на лягушках. d-Тубокурарин (0,1 
Ммоль/л) избирательно угнетает кванты ЭЭГ, CdCl2 
(10 - 200 Мкмоль/л) полностью угнетает кванты 
ЭЭГ. В отличие от последних этанол (0.2 - 0.5 
моль/л) повышает пресинаптические пики. Парал­
лельно в работе изучались возможности разграни­
чения между пре- и постсинаптическими рецепто­
рами. 
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СЕЗОННЫЕ ИЗМЕНЕНИЯ СИСТЕМНОГО АРТЕРИАЛЬНОГО 
ДАВЛЕНИЯ, ЧАСТОТЫ ПУЛЬСА, ВНУТРИМ03Г0В0Г0 
КРОВОТОКА И СОДЕРЖАНИЯ МОНОАМИНОВ В МОЗГЕ 
КРОЛИКОВ 
М.Я. Оттер, A.B. Шоттер 
Р е з ю м е  
В долголетних опытах на кроликах, проводи­
мых ежемесячно, было выяснено, что системное ар­
териальное давление (САД), частота пульса (ЧП), 
внутримозговой 
кровоток (ВМК) и содержание моно­
аминов - норадреналина (НА) , дофамина (ДА), и 
серотонина (5-ОТ) - имеют сезонные варианты. Вес­
ной САД и ВКТ у кроликов понижаются, частота 
пульса повышается. Наряду с этим весной, особенно 
в мае месяце, наблюдается и максимальное содер­
жание НА и 5-ОТ в мозге кролика, содержание ДА 
наоборот, понижено. Причиной понижения САД может 
служить и понижение содержания ДА, т.к. ДА играет 
роль вазоконструкции. Понижение САД весной может 
быть связано с характером анестезии у кроликов в 
этот сезон. Глубина анестезии, в свою очередь, 
коррелируется повышением содержания НА и 5-ОТ. 
РАЗВИТИЕ ПРЕПОДАВАНИЯ ФАРМАКОЛОГИИ В 
ТАРТУСКОМ УНИВЕРСИТЕТЕ ЗА ПЕРИОД 1944-1989 гг .  
Л.Б. Нурманд 
Р е з ю м е  
В статье приводятся краткие сведения о сос­
тоянии кафедры фармакологии в послевоенные годы и 
о ее развитии до настоящего времени. За этот 
период объем курса фармакологии расширился вдвое, 
в то время как количество часов осталось практи­
чески неизмененным. Кроме издания учебников (3) и 
учебно-методических пособий, надо было ввести 
существенные изменения в лекционный курс, лабора­
торные занятия и систему контроля. В частности, 
подробное изложение 
отдельных препаратов на лек­
циях ввиду огранниченности времени и обширности 
материала было заменено ознакомлением студентов с 
общими свойствами отдельных групп лекарственных 
веществ, экспериментальные работы - семинарскими 
занятиями и решением ситуационных задач, были 
введены коллоквиумы по основным главам фармако­
логии 
. 
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